0001104659-24-052471 8-K 15 20240425 1.01 9.01 20240426 20240426 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 8-K 34 001-39202 24878918 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 8-K 1 tm2412796d1_8k.htm FORM 8-K
false 0001477845 0001477845 2024-04-25 2024-04-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 25, 2024

  

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

     
Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

101 Lindenwood Drive, Suite 225
Malvern
, PA 19355

(Address of Principal Executive Offices, and Zip Code)

 

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 25, 2024, Annovis Bio, Inc., a Delaware corporation (the “Company”), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with the Equity Line investor (the “ELOC Purchaser”), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to 2,051,428 shares of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) (but subject to the limitations described below). Under the Purchase Agreement, the Company has agreed to issue to the ELOC Purchaser shares of Common Stock with a total value of $375,000 as commitment shares (the “Commitment Shares”), with 10,181 shares being delivered on the date of the Purchase Agreement and the remaining shares to be delivered on the 90th and 180th day thereafter. Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with the ELOC Purchaser, pursuant to which it agreed to provide the ELOC Purchaser with certain registration rights related to the shares issued under the Purchase Agreement (the “Registration Rights Agreement”).

 

The Company may, from time to time and at its sole discretion, direct the ELOC Purchaser to purchase shares of Common Stock upon the satisfaction of certain conditions set forth in the Purchase Agreement at a purchase price per share based on the market price of Common Stock at the time of sale as computed under the Purchase Agreement. There is no upper limit on the price per share that The ELOC Purchaser could be obligated to pay for Common Stock under the Purchase Agreement. The Company will control the timing and amount of any sales of Common Stock to The ELOC Purchaser, and The ELOC Purchaser has no right to require the Company to sell any shares to it under the Purchase Agreement. Actual sales of shares of Common Stock to The ELOC Purchaser under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time.

 

Under the applicable NYSE rules, in no event may the Company issue to The ELOC Purchaser under the Purchase Agreement more than 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the “Exchange Cap”), unless (i) the Company obtains stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with applicable NYSE, or (ii) the price per share paid by The ELOC Purchaser for all of the shares of Common Stock purchased from the Company pursuant to the Purchase Agreement, if any, equals or exceeds the lower of (A) the official closing price of the Common Stock immediately preceding delivery of the purchase notice to The ELOC Purchaser and (B) the average of the closing sale prices of the Common Stock for the five (5) trading days immediately preceding the delivery of the purchase notice.

 

In all cases, the Company may not issue or sell any shares of Common Stock to The ELOC Purchaser under the Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by The ELOC Purchaser and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder), would result in The ELOC Purchaser beneficially owning more than 4.99% of the outstanding shares of Common Stock.

 

 

 

 

The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its Common Stock to the ELOC Purchaser. The Company expects that any proceeds received by it from such sales to the ELOC Purchaser will be used for working capital and general corporate purposes.

 

The Purchase Agreement contains customary representations, warranties and agreements of the Company and Keystone, limitations and conditions regarding sales of Common Stock, indemnification rights and other obligations of the parties.

 

There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement other than a prohibition (with certain limited exceptions) on entering into a dilutive securities transaction during certain periods when the Company is selling Common Stock to the ELOC Purchaser under the Purchase Agreement. The ELOC Purchaser has agreed that, during the term of the Purchase Agreement, it will not engage in or effect, directly or indirectly, any short sales involving the Company’s securities or any hedging transaction that transfers the economic risk of ownership of the Common Stock.

 

The Purchase Agreement will automatically terminate on the earliest to occur of (i) the expiration of the Registration Statement, (ii) the date on which Keystone shall have purchased from the Company under the Purchase Agreement the aggregate limit of 2,051,428 shares of Common Stock, (iii) the date on which the Common Stock shall have failed to be listed or quoted on the NYSE or another U.S. national securities exchange identified as an “eligible market” in the Purchase Agreement, (iv) the 30th trading day after the date on which a voluntary or involuntary bankruptcy proceeding involving the Company has been commenced that is not discharged or dismissed prior to such trading day, and (v) the date on which a bankruptcy custodian is appointed for all or substantially all of the Company’s property or the Company makes a general assignment for the benefit of creditors. The Company has the right to terminate the Purchase Agreement at any time after the Commencement Date (as defined in the Purchase Agreement), at no cost or penalty, upon one trading day’s prior written notice to the ELOC Purchaser. The ELOC Purchaser has the right to terminate the Purchase Agreement upon ten trading days’ prior written notice to the Company if certain specified events occur. The Company and the ELOC Purchaser may also agree to terminate the Purchase Agreement by mutual written consent. Neither the Company nor the ELOC Purchaser may assign or transfer the Company’s respective rights and obligations under the Purchase Agreement.

 

The offer and sale of the securities that may be issued and sold under the Purchase Agreement (including Commitment Shares), and the resale of such securities by the ELOC Purchaser, are registered under the Securities Act of 1933, as amended (the “Securities Act”), under the Company’s shelf registration statement on Form S-3 (File No. 333-276814) (the “Registration Statement”), and the related base prospectus, dated February 12, 2024, as supplemented by a prospectus supplement to be filed with the SEC pursuant to Rule 424(b) under the Securities Act.

 

Copies of the Purchase Agreement and Registration Rights Agreement are filed herewith as Exhibits 10.1 and 10.2 and are incorporated herein by reference. The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to such exhibits.

 

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of Common Stock, nor shall there be any sale of shares of Common Stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 

Item. 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number   Exhibit Description
10.1   Common Stock Purchase Agreement dated as of April 25, 2024 between Annovis Bio, Inc. and the ELOC Purchaser Capital Partners, LLC
10.2   Registration Rights Agreement dated as of April 25, 2024 between Annovis Bio, Inc. and the ELOC Purchaser Capital Partners, LLC
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: April 26, 2024 By:

/s/ Maria Maccecchini

    Name: Maria Maccecchini
    Title: President and Chief Executive Officer

 

 

EX-10.1 2 tm2412796d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

COMMON STOCK PURCHASE AGREEMENT

 

Dated as of April 25, 2024

 

by and among

 

ANNOVIS BIO, INC.,

 

and

 

KEYSTONE CAPITAL PARTNERS, LLC

 

 

 

 

Table of Contents

 

Page

 

Article I PURCHASE AND SALE OF COMMON STOCK 2
Section 1.1. Purchase and Sale of Stock 2
Section 1.2. Closing Date; Settlement Dates 2
Section 1.3. Initial Public Announcements and Required Filings 3
     
Article II PURCHASE TERMS 3
Section 2.1. Fixed Purchases 3
Section 2.2. VWAP Purchases 4
Section 2.3. Additional VWAP Purchases 5
Section 2.4. Compliance with Rules of Trading Market 6
Section 2.5. Beneficial Ownership Limitation 6
Section 2.6. Commitment Shares 7
     
Article III REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR 7
Section 3.1. Organization and Standing of the Investor 7
Section 3.2. Authorization and Power 7
Section 3.3. No Conflicts 8
Section 3.4. Investment Purpose 8
Section 3.5. Accredited Investor Status 8
Section 3.6. Reliance on Exemptions 8
Section 3.7. Information 9
Section 3.8. No Governmental Review 9
Section 3.9. No General Solicitation 9
Section 3.10. Not an Affiliate 9
Section 3.11. No Prior Short Sales 10
Section 3.12. Statutory Underwriter Status 10
     
Article IV REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY 10
Section 4.1. Organization, Good Standing and Power 10
Section 4.2. Authorization, Enforcement 11
Section 4.3. Capitalization 11
Section 4.4. Issuance of Securities 12
Section 4.5. No Conflicts 12
Section 4.6. Commission Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants 13
Section 4.7. Subsidiaries 14
Section 4.8. No Material Adverse Effect or Material Adverse Change, No Undisclosed Liabilities 14
Section 4.9. No Undisclosed Events or Circumstances 15
Section 4.10. Indebtedness 15
Section 4.11. Title to Assets 16
Section 4.12. Actions Pending 16
Section 4.13. Compliance With Laws 16

 

i 

 

 

Section 4.14. Certain Fees 16
Section 4.15. Operation of Business 16
Section 4.16. Environmental Compliance 17
Section 4.17. Material Agreements 17
Section 4.18. Transactions With Affiliates 17
Section 4.19. Intellectual Property Rights 17
Section 4.20. Use of Proceeds 18
Section 4.21. Investment Company Act Status 18
Section 4.22. Benefit Plans; Labor Matters 18
Section 4.23. Taxes 18
Section 4.24. Insurance 19
Section 4.25. Dilutive Effect 19
Section 4.26. Manipulation of Price 19
Section 4.27. Securities Act 19
Section 4.28. Listing and Maintenance Requirements; DTC Eligibility 20
Section 4.29. Application of Takeover Protections 20
Section 4.30. Foreign Corrupt Practices 20
Section 4.31. Money Laundering Laws 20
Section 4.32. OFAC 21
Section 4.33. Information Technology; Compliance with Data Privacy Laws 21
Section 4.34. No Disqualification Events 21
Section 4.35. ERISA 22
Section 4.36. No Other Similar Agreement 22
Section 4.37. Acknowledgement Regarding Investor’s Acquisition of Securities 22
     
Article V ADDITIONAL COVENANTS 22
Section 5.1. Securities Compliance 22
Section 5.2. Reservation of Common Stock 23
Section 5.3. Registration and Listing 23
Section 5.4. Compliance with Laws 24
Section 5.5. Keeping of Records and Books of Account; Due Diligence 24
Section 5.6. No Frustration; Prohibition of Certain Issuances Before Settlement of Purchases; No Similar Transactions 25
Section 5.7. Corporate Existence 27
Section 5.8. Fundamental Transaction 27
Section 5.9. Selling Restrictions 27
Section 5.10. Effective Registration Statement 28
Section 5.11. Blue Sky 28
Section 5.12. Non-Public Information 28
Section 5.13. Broker/Dealer 29
Section 5.14. Disclosure Schedules 29
Section 5.15. Delivery of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events 30
     
Article VI CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES 30
Section 6.1. Conditions Precedent to Closing 30

 

ii 

 

 

Section 6.2. Conditions Precedent to Commencement 31
Section 6.3. Conditions Precedent to Purchases by Investor 35
     
Article VII TERMINATION 39
Section 7.1. Automatic Termination; Termination by Consent 39
Section 7.2. Other Termination 39
Section 7.3. Effect of Termination 40
     
Article VIII INDEMNIFICATION 41
Section 8.1. Indemnification of Investor 41
Section 8.2. Indemnification Procedures 42
     
Article IX MISCELLANEOUS 43
Section 9.1. Certain Fees and Expenses; Commitment Shares; Commencement Irrevocable Transfer Agent Instructions 43
Section 9.2. Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial 45
Section 9.3. Entire Agreement 46
Section 9.4. Notices 46
Section 9.5. Waivers 47
Section 9.6. Amendments 47
Section 9.7. Headings 47
Section 9.8. Construction 47
Section 9.9. Binding Effect 47
Section 9.10. No Third Party Beneficiaries 47
Section 9.11. Governing Law 48
Section 9.12. Survival 48
Section 9.13. Counterparts 48
Section 9.14. Publicity 48
Section 9.15. Severability 48
Section 9.16. Further Assurances 48

 

ANNEX 2.1 TO THE COMMON STOCK PURCHASE AGREEMENT FORM OF FIXED PURCHASE NOTICE C-3  
ANNEX 2.2 TO THE COMMON STOCK PURCHASE AGREEMENT FORM OF VWAP PURCHASE NOTICE C-4  
ANNEX 2.2B TO THE COMMON STOCK PURCHASE AGREEMENT FORM OF VWAP PURCHASE CONFIRMATION C-5  
ANNEX 2.3 TO THE COMMON STOCK PURCHASE AGREEMENT FORM OF ADDITIONAL VWAP PURCHASE NOTICE C-6  

 

iii 

 

 

COMMON STOCK PURCHASE AGREEMENT

 

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of April 25, 2024 (this “Agreement”), by and between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”) and Annovis Bio, Inc., a Delaware corporation (the “Company”).

 

RECiTALS

 

WHEREAS, the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to 19.99% of the Company’s outstanding shares of Common Stock as of the date of this Agreement (to the extent applicable under Section 2.4 hereof), unless (i) stockholder approval is obtained to issue more than such 19.99% or (ii) the price of applicable sales of Common Stock to the Investor under this Agreement equals or exceeds the lower of (A) the official Closing Sale Price on the NYSE immediately preceding the delivery of the applicable Fixed Purchase notice, VWAP Purchase notice, or Additional VWAP Purchase notice to the Investor and (B) the average of the Closing Sale Prices of the Common Stock on the NYSE for the five trading days immediately preceding the delivery of such Fixed Purchase notice, VWAP Purchase notice or Additional VWAP Purchase Notice, as applicable (in each case plus an incremental amount to take into account the Commitment Shares), such that the sales of such Common Stock to the Investor would not count toward the 19.99% because they are “at market” under applicable NYSE rules;

 

WHEREAS, in consideration for the Investor’s execution and delivery of this Agreement, the Company shall cause its Transfer Agent to issue to the Investor the Commitment Shares in accordance with the terms and subject to the conditions of this Agreement;

 

WHEREAS, such sales of Common Stock by the Company to the Investor will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act (“Section 4(a)(2)”) and Rule 506(b) of Regulation D promulgated by the Commission under the Securities Act (“Regulation D”), and upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all of the sales of Common Stock to the Investor to be made hereunder;

 

WHEREAS, the parties hereto are concurrently entering into a Registration Rights Agreement in the form attached as Exhibit A hereto (the “Registration Rights Agreement”), pursuant to which the Company shall provide Investor with certain registration rights related to the shares issued under this Agreement, upon the terms and subject to the conditions set forth therein.

 

1

 

 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 

Article I
PURCHASE AND SALE OF COMMON STOCK

 

Section 1.1.          Purchase and Sale of Stock. Upon the terms and subject to the conditions of this Agreement, during the Investment Period, the Company, in its sole discretion, shall have the right, but not the obligation, to issue and sell to the Investor, and the Investor shall purchase from the Company, up to 19.99% of the Company’s outstanding shares of Common Stock as of the date of this Agreement, including the Commitment Shares, unless (i) stockholder approval is obtained to issue more than such 19.99% or (ii) the price of applicable sales of Common Stock to the Investor under this Agreement equals or exceeds the lower of (A) the official Closing Sale Price on the NYSE immediately preceding the delivery of the applicable Fixed Purchase notice, VWAP Purchase notice, or Additional VWAP Purchase notice to the Investor and (B) the average of the Closing Sale Prices of the Common Stock on the NYSE for the five trading days immediately preceding the delivery of such Fixed Purchase notice, VWAP Purchase notice or Additional VWAP Purchase Notice, as applicable (in each case plus an incremental amount to take into account the Commitment Shares), such that the sales of such Common Stock to the Investor would not count toward the 19.99% because they are “at market” under applicable NYSE rules (the “Total Purchase Commitment”), to the extent applicable under Section 2.4, by the delivery to the Investor of Fixed Purchase Notices, VWAP Purchase Notices, or Additional VWAP Purchase Notices, as provided in Article II.

 

Section 1.2.          Closing Date; Settlement Dates. This Agreement shall become effective and binding (the “Closing”) upon (a) the delivery by the Company to its Transfer Agent of irrevocable instructions to issue the Initial Commitment Shares to the Investor or its designees as provided in Sections 6.1 and 9.1(ii), (b) the delivery of counterpart signature pages of this Agreement and the Registration Rights Agreement executed by each of the parties hereto and thereto, and (c) the delivery of all other documents, instruments and writings required to be delivered at the Closing, in each case as provided in Section 6.1, to the offices of Pryor Cashman LLP, 7 Times Square, New York, NY 10036, at 1:00 p.m., New York City time, on the Closing Date, or such other time and place as the parties hereto shall agree. In consideration of, and in express reliance upon, the representations, warranties and covenants contained in, and upon the terms and subject to the conditions of, this Agreement, during the Investment Period the Company, at its sole option and discretion, may issue and sell to the Investor, and, if the Company elects to so issue and sell, the Investor shall purchase from the Company, the Shares in respect of each Fixed Purchase, VWAP Purchase and Additional VWAP Purchase (each, a “Settlement”). The payment for the Shares in respect of each Fixed Purchase, VWAP Purchase and Additional VWAP Purchase shall occur (i) on the second (2nd) Trading Day following delivery of the Shares by the Company, and (ii) in accordance with Article II hereof; provided, that all of the conditions precedent in Article VII shall have been fulfilled at the applicable times set forth in Article VII.

 

2

 

 

Section 1.3.          Initial Public Announcements and Required Filings. The Company shall, within the time period required under the Exchange Act, file with the Commission a Current Report on Form 8-K describing the material terms of the transactions contemplated by the Transaction Documents, including, without limitation, the issuance of the Commitment Shares to the Investor, and attaching as exhibits thereto copies of each of this Agreement, the Registration Rights Agreement and, if applicable, any press release issued by the Company disclosing the execution of this Agreement by the Company (including all exhibits thereto, the “Current Report”). The Company shall provide the Investor a reasonable opportunity to comment on a draft of the Current Report prior to filing the Current Report with the Commission and shall give due consideration to all such comments. From and after the filing of the Current Report with the Commission, the Company shall have publicly disclosed all material, nonpublic information delivered to the Investor (or the Investor’s representatives or agents) by the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, agents or representatives (if any) in connection with the transactions contemplated by the Transaction Documents. The Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in this Section 1.3, the Investor shall maintain the confidentiality of all disclosures made to it in connection with the transactions contemplated by the Transaction Documents (including the existence and terms of the transactions), except that the Investor may disclose the terms of such transactions to its financial, accounting, legal and other advisors (provided that the Investor directs such Persons to maintain the confidentiality of such information). The Company shall use its commercially reasonable efforts to prepare and, as soon as practicable, but in no event later than the applicable Filing Deadline, file with the Commission the Initial Prospectus Supplement and any New Registration Statement covering only the resale by the Investor of the Registrable Securities in accordance with the Securities Act and the Registration Rights Agreement. At or before 8:30 a.m. (New York City time) on the Trading Day immediately following the Effective Date of the Initial Prospectus Supplement and any New Registration Statement (or any post-effective amendment thereto), the Company shall use its commercially reasonable efforts to file with the Commission in accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment thereto).

 

Article II
PURCHASE TERMS

 

Subject to the satisfaction or (to the extent permitted by applicable law) waiver of the conditions set forth in this Agreement, the parties agree (unless otherwise mutually agreed upon by the parties in writing) as follows:

 

Section 2.1.          Fixed Purchases. Upon the initial satisfaction or waiver of all of the conditions set forth in set forth in Section 6.2, (the “Commencement” and the date of initial satisfaction of all of such conditions, the “Commencement Date”) and from time to time thereafter, subject to the satisfaction or waiver of all of the conditions set forth in Section 6.3, and on any business day selected by the Company where the Closing Sale Price on the applicable national market, or quotation service, is equal to or greater than $5.00, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a Fixed Purchase Notice, to purchase a Fixed Purchase Share Amount, not to exceed the applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date), at the applicable Fixed Purchase Price therefor on the applicable Fixed Purchase Date in accordance with this Agreement (each such purchase a “Fixed Purchase”); provided, however, that the Investor’s committed obligation under any single Fixed Purchase shall not exceed the lower of 25,000 shares of Common Stock or $250,000 (provided that all shares of Common Stock in respect of all prior Fixed Purchases, VWAP Purchases and Additional VWAP Purchases shall have been delivered to the Investor via Deposit/Withdrawal at Custodian (“DWAC”)). If the Company delivers any Fixed Purchase Notice directing the Investor to purchase a Fixed Purchase Share Amount in excess of the applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date), such Fixed Purchase Notice shall be void ab initio to the extent of the amount by which the Fixed Purchase Share Amount set forth in such Fixed Purchase Notice exceeds such applicable Fixed Purchase Maximum Amount, and the Investor shall have no obligation to purchase such excess Shares in respect of such Fixed Purchase Notice; provided, however, that the Investor shall remain obligated to purchase the applicable Fixed Purchase Maximum Amount in such Fixed Purchase. The Company may deliver a Fixed Purchase Notice, in the Form attached hereto as Annex 2.1, to the Investor as often as every Trading Day, so long as (i) the Closing Sale Price of the Common Stock on such Trading Day is not less than $5.00 and (ii) all Shares subject to all prior Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices (as applicable) have theretofore been received by the Investor as DWAC Shares. Since delivery of a Fixed Purchase Notice is made by the Company after market close on the applicable Fixed Purchase Date, the Fixed Purchase Price is determined and fixed at the time the Company delivers the Fixed Purchase to the Investor.

 

3

 

 

Section 2.2.          VWAP Purchases. Upon the initial satisfaction or waiver of all of the conditions set forth in set forth in Section 6.2, on the Commencement Date and from time to time thereafter, and on any business day selected by the Company where the Closing Sale Price on the applicable national market, or quotation service is equal to or greater than $5.00, subject to the satisfaction of all of the conditions set forth in Section 6.3, in addition to purchases of Shares as described in Section 2.1, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a VWAP Purchase Notice, to purchase the applicable VWAP Purchase Share Amount, not to exceed the applicable VWAP Purchase Maximum Amount, at the applicable VWAP Purchase Price therefor on the applicable VWAP Purchase Date in accordance with this Agreement (each such purchase, a “VWAP Purchase”); provided, however, that the Investor’s aggregate committed obligation under a VWAP Purchase and all Additional VWAP Purchases shall not exceed $10,000,000 in the aggregate for such VWAP Purchase and all such Additional VWAP Purchases, collectively. The Company may deliver VWAP Purchase Notice, in the Form attached hereto as Annex 2.2, to the Investor only (i) on a Trading Day on which the Company also properly submitted a Fixed Purchase Notice providing for a Fixed Purchase of an amount of Shares not less than the applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date), (ii) if all Shares subject to all prior Fixed Purchase Notices, VWAP Purchase Notices, and Additional VWAP Purchase Notices (as applicable) have theretofore been received by the Investor as DWAC Shares and (iii) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice for the corresponding Fixed Purchase have traded since the VWAP Purchase Commencement Time. The Investor is obligated to accept each VWAP Purchase Notice prepared and delivered by the Company in accordance with the terms of and subject to the satisfaction of the conditions contained in this Agreement. If the Company delivers any VWAP Purchase Notice directing the Investor to purchase a VWAP Purchase Share Amount in excess of the applicable VWAP Purchase Maximum Amount that the Company is then permitted to include in such VWAP Purchase Notice, such VWAP Purchase Notice shall be void ab initio to the extent of the amount by which the VWAP Purchase Share Amount set forth in such VWAP Purchase Notice exceeds such applicable VWAP Purchase Maximum Amount, and the Investor shall have no obligation to purchase such excess Shares in respect of such VWAP Purchase Notice; provided, however, that the Investor shall remain obligated to purchase the applicable VWAP Purchase Maximum Amount in such VWAP Purchase At or prior to 9:30 a.m., New York City time, on the Trading Day immediately following the VWAP Purchase Date for each VWAP Purchase, the Investor shall provide to the Company a written confirmation of such VWAP Purchase setting forth the applicable VWAP Purchase Share Amount and VWAP Purchase Price for such VWAP Purchase (each, a “VWAP Purchase Confirmation”).

 

4

 

 

Section 2.3.          Additional VWAP Purchases. Upon the initial satisfaction or waiver of all of the conditions set forth in set forth in Section 6.3 on the Commencement Date and from time to time thereafter, subject to the satisfaction of all of the conditions set forth in Section 6.3, in addition to purchases of Shares as described in Section 2.1 and Section 2.2, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Additional VWAP Purchase Notice, to purchase the applicable Additional VWAP Purchase Share Amount, not to exceed the applicable Additional VWAP Purchase Maximum Amount, at the applicable Additional VWAP Purchase Price therefor on the applicable Additional VWAP Purchase Date in accordance with this Agreement (each such purchase, an “Additional VWAP Purchase”); provided, however, that the Investor’s aggregate committed obligation under a VWAP Purchase and all Additional VWAP Purchases, the applicable Additional VWAP Purchase Date therefor is the same Trading Day as the applicable VWAP Purchase Date for such VWAP Purchase, shall not exceed $10,000,000 in the aggregate for such VWAP Purchase and all such Additional VWAP Purchases, collectively. The Company may deliver an Additional VWAP Purchase Notice, in the Form attached hereto as Annex 2.3, to the Investor only (i) on a Trading Day that is also the VWAP Purchase Date for a VWAP Purchase with respect to which the Company properly submitted to the Investor a VWAP Purchase Notice in accordance with this Agreement on the applicable Fixed Purchase Date for a Fixed Purchase of an amount of Shares not less than the applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date), (ii) if all Shares subject to all prior Fixed Purchase Notices, VWAP Purchase Notices, and Additional VWAP Purchase Notices, including, without limitation, all prior VWAP Purchases and Additional VWAP Purchases effected on the same Trading Day as the Additional VWAP Purchase Date on which the applicable Additional VWAP Purchase is to be effected, as applicable, have theretofore been received by the Investor as DWAC Shares and (iii) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding VWAP Purchase Notice for the corresponding VWAP Purchase have traded since the Additional VWAP Purchase Commencement Time. The Investor is obligated to accept each Additional VWAP Purchase Notice prepared and delivered by the Company in accordance with the terms of and subject to the satisfaction of the conditions contained in this Agreement. If the Company delivers any Additional VWAP Purchase Notice directing the Investor to purchase an Additional VWAP Purchase Share Amount in excess of the applicable Additional VWAP Purchase Maximum Amount that the Company is then permitted to include in such Additional VWAP Purchase Notice, such Additional VWAP Purchase Notice shall be void ab initio to the extent of the amount by which the Additional VWAP Purchase Share Amount set forth in such Additional VWAP Purchase Notice exceeds such applicable Additional VWAP Purchase Maximum Amount, and the Investor shall have no obligation to purchase such excess Shares in respect of such Additional VWAP Purchase Notice; provided, however, that the Investor shall remain obligated to purchase the applicable Additional VWAP Purchase Maximum Amount in such Additional VWAP Purchase At or prior to 9:30 a.m., New York City time, on the Trading Day immediately following the Additional VWAP Purchase Date for each Additional VWAP Purchase, the Investor shall provide to the Company a written confirmation of such Additional VWAP Purchase setting forth the applicable Additional VWAP Purchase Share Amount and Additional VWAP Purchase Price for such Additional VWAP Purchase (each, an “Additional VWAP Purchase Confirmation”).

 

5

 

 

Section 2.4.           Compliance with Rules of Trading Market.

 

(a)           Share Issuance Restriction. The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the transactions contemplated hereby, including the Commitment Shares, would exceed 2,051,428 (representing 19.99% of the shares of Common Stock issued and outstanding immediately prior to the execution of this Agreement, but not counting any such sales of such Common Stock to the Investor that would not count toward the 19.99% because they are “at market” under applicable NYSE rules), which number of shares shall be reduced, on a share-for-share basis, by the number of shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated by this Agreement under applicable rules of the Trading Market (such maximum number of shares of Common Stock issuable by the Company under this Agreement, the “Aggregate Limit”).

 

(b)           General. The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement if such issuance or sale would reasonably be expected to result in (A) a violation of the Securities Act or (B) a breach of the rules of the Trading Market. The provisions of this Section 2.4 shall be implemented in a manner otherwise than in strict conformity with the terms of this Section 2.4 only if necessary to ensure compliance with the Securities Act and the applicable rules of the Trading Market.

 

Section 2.5.           Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor and its Affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 4.99% of the outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the written or oral request of the Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent is open for business) confirm orally or in writing to the Investor the number of shares of Common Stock outstanding as of the most recent date for which the Transfer Agent has such information. The Investor and the Company shall each cooperate in good faith in the determinations required under this Section 2.5 and the application of this Section 2.5. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error. The provisions of this Section 2.5 shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2.5 to the extent necessary to properly give effect to the limitations contained in this Section 2.5.

 

6

 

 

Section 2.6.           Commitment Shares. In consideration for the Investor’s execution and delivery of this Agreement, concurrently with the execution and delivery of this Agreement on the Closing Date, the Company shall deliver irrevocable instructions to its Transfer Agent to issue to the Investor or its designee(s) the Initial Commitment Shares, as DWAC Shares, not later than 4:00 p.m. (New York City time) on the Closing Date, and prior to the delivery of the initial Fixed Purchase Notice. The Commitment Shares (not including the Back End Commitment Shares) shall be included in the initial Prospectus Supplement to be freely tradable and transferable and without restriction on resale and without any stop transfer instructions maintained against the transfer thereof. Additionally, in further consideration for the Investor’s execution and delivery of this Agreement, the Company shall deliver (i) on the ninetieth (90th) calendar day following the Commencement Date, irrevocable instructions to its Transfer Agent to issue to the Investor or its designee(s) the First Back End Commitment Shares, (ii) on the one hundred and eightieth (180th) calendar day following the Commencement Date, irrevocable instructions to its Transfer Agent to issue to the Investor or its designee(s) the Second Back End Commitment Shares, as applicable, as DWAC Shares, such that each of the Initial Commitment Shares, First Back End Commitment Share and Second Back End Commitment Shares are credited to the Investor’s or its designee’s specified DWAC account with DTC under its FAST Program not later than 4:00 p.m. (New York City time) on their respective due date. For the avoidance of doubt, all of the Commitment Shares, including the Back End Commitment Shares, shall be fully earned as of the Closing Date, regardless of whether any Fixed Purchases or VWAP Purchases are effected hereunder and regardless of any subsequent termination of this Agreement. In the event of a termination of this Agreement prior to the 90th calendar day or 180th calendar day following the Commencement Date, any unpaid Commitment Shares shall be paid at that date.

 

Article III
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR

 

The Investor hereby makes the following representations, warranties and covenants to the Company:

 

Section 3.1.           Organization and Standing of the Investor. The Investor is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.

 

Section 3.2.           Authorization and Power. The Investor has the requisite limited liability company power and authority to enter into and perform its obligations under this Agreement and the Registration Rights Agreement and to purchase or acquire the Securities in accordance with the terms hereof. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary limited liability company action, and no further consent or authorization of the Investor, its Board of Directors or its members is required. Each of this Agreement and the Registration Rights Agreement has been duly executed and delivered by the Investor and constitutes a valid and binding obligation of the Investor enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including any limitation of equitable remedies).

 

7

 

 

Section 3.3.           No Conflicts. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement and the consummation by the Investor of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation of such Investor’s certificate of formation, limited liability company agreement or other applicable organizational instruments, (ii) conflict with, constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Investor is a party or is bound, (iii) create or impose any lien, charge or encumbrance on any property of the Investor under any agreement or any commitment to which the Investor is party or under which the Investor is bound or under which any of its properties or assets are bound, or (iv) result in a violation of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any court or governmental agency applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, prohibit or otherwise interfere with, in any material respect, the ability of the Investor to enter into and perform its obligations under this Agreement and the Registration Rights Agreement. The Investor is not required under any applicable federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement and the Registration Rights Agreement or to purchase or acquire the Securities in accordance with the terms hereof; provided, however, that for purposes of the representation made in this sentence, the Investor is assuming and relying upon the accuracy of the relevant representations and warranties and the compliance with the relevant covenants and agreements of the Company in the Transaction Documents to which it is a party.

 

Section 3.4.           Investment Purpose. The Investor is acquiring the Securities for its own account, for investment purposes and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or exempt from the registration requirements of the Securities Act; provided, however, that by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with, or pursuant to, a registration statement filed pursuant to the Registration Rights Agreement or an applicable exemption under the Securities Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell or distribute any of the Securities.

 

Section 3.5.           Accredited Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

Section 3.6.           Reliance on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of U.S. federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the Securities.

 

8

 

 

Section 3.7.           Information. All materials relating to the business, financial condition, management and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Investor have been furnished or otherwise made available to the Investor or its advisors, including, without limitation, the Commission Documents. The Investor understands that its investment in the Securities involves a high degree of risk. The Investor is able to bear the economic risk of an investment in the Securities and has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of a proposed investment in the Securities. The Investor and its advisors have been afforded the opportunity to ask questions of and receive answers from representatives of the Company concerning the financial condition and business of the Company and other matters relating to an investment in the Securities. Neither such inquiries nor any other due diligence investigations conducted by the Investor or its advisors, if any, or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement or in any other Transaction Document to which the Company is a party or the Investor’s right to rely on any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby (including, without limitation, the opinions of the Company’s counsel delivered pursuant to Section 6.2(xvi)). The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. The Investor understands that it (and not the Company) shall be responsible for its own tax liabilities that may arise as a result of this investment or the transactions contemplated by this Agreement. The Investor is aware of all of its obligations under U.S. federal and applicable state securities laws and all rules and regulations promulgated thereunder in connection with this Agreement and the transactions contemplated hereby and the purchase and sale of the Securities.

 

Section 3.8.           No Governmental Review. The Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

Section 3.9.           No General Solicitation. The Investor is not purchasing or acquiring the Securities as a result of any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities.

 

Section 3.10.         Not an Affiliate. The Investor is not an officer, director or an Affiliate of the Company. As of the date of this Agreement, the Investor does not beneficially own any shares of Common Stock or securities exercisable for or convertible into shares of Common Stock, and during the Restricted Period, Investor will not acquire beneficial ownership of any shares of the Company’s capital stock (including shares of Common Stock or securities exercisable for or convertible into shares of Common Stock) other than pursuant to this Agreement; provided, however, that nothing in this Agreement shall prohibit or be deemed to prohibit the Investor from purchasing, in an open market transaction or otherwise, shares of Common Stock necessary to make delivery by the Investor in satisfaction of a sale by the Investor of Shares that the Investor anticipated receiving from the Company in connection with the settlement of a Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as applicable, if the Company or the Transfer Agent shall have failed for any reason to electronically transfer all of the Shares subject to such Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as applicable, to the Investor by crediting the Investor’s or its designated Broker-Dealer’s account at DTC through its DWAC delivery system, at or prior to the applicable time required by and otherwise in compliance with Section 2.4 of this Agreement.

 

9

 

 

Section 3.11.         No Prior Short Sales. At no time prior to the date of this Agreement has any of the Investor, its agents, representatives or Affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock.

 

Section 3.12.         Statutory Underwriter Status. The Investor acknowledges that it will be disclosed as an “underwriter” and a “selling stockholder” in the Initial Prospectus Supplement and any New Registration Statement and in any Prospectus contained therein to the extent required by applicable law.

 

Section 3.13         Resales of Securities. The Investor represents, warrants and covenants that it will resell Securities purchased or acquired by the Investor from the Company pursuant to this Agreement only in a manner described under the caption “Plan of Distribution” in the Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations.

 

Article IV
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

 

Except as set forth in the Commission Documents or in the disclosure schedule delivered by the Company to the Investor (which is hereby incorporated by reference in, and constitutes an integral part of, this Agreement) (the “Disclosure Schedule”), the Company hereby makes the following representations, warranties and covenants to the Investor:

 

Section 4.1.           Organization, Good Standing and Power. The Company is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. The Company is not in violation or default of any of the provisions of its certificate of incorporation or bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

10

 

 

Section 4.2.           Authorization, Enforcement. The Company has the requisite corporate power and authority to enter into and perform its obligations under each of the Transaction Documents to which it is a party and to issue the Securities in accordance with the terms hereof and thereof. Except for approvals of the Company’s Board of Directors or a committee thereof as may be required in connection with any issuance and sale of Shares to the Investor hereunder (which approvals shall be obtained prior to the delivery of any Fixed Purchase Notice, any VWAP Purchase Notice and any Additional VWAP Purchase Notice), the execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation by it of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate action on the part of the Company, and no further consent or authorization of the Company or its Board of Directors or its stockholders, is required in order for the Company to execute, deliver and perform its respective obligations under the Transaction Documents to which it is a party. Each of the Transaction Documents to which the Company is a party has been duly executed and delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including any limitation of equitable remedies).

 

Section 4.3.           Capitalization. All the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable. Except as set forth in the Commission Documents and this Agreement, there are no agreements or arrangements under which the Company is obligated to register the sale of any securities under the Securities Act. Except as set forth in the Commission Documents, no shares of capital stock of the Company are entitled to preemptive rights and there are no outstanding debt securities and no contracts, commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company other than those issued or granted in the ordinary course of business pursuant to the Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth in the Commission Documents, the Company is not a party to, and it has no Knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except as set forth in the Commission Documents, there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by this Agreement or any of the other Transaction Documents or the consummation of the transactions described herein or therein. The Company has made available via EDGAR true and correct copies of the Company’s Certificate of Incorporation as in effect on the Commencement Date (the “Charter”), and the Company’s Bylaws as in effect on the Commencement Date (the “Bylaws”).

 

11

 

 

Section 4.4.           Issuance of Securities. The Commitment Shares have been, and the Shares to be issued under this Agreement have been, or with respect to Shares to be purchased by the Investor pursuant to a particular Fixed Purchase Notice, a particular VWAP Purchase Notice or a particular Additional VWAP Purchase Notice, will be, prior to the delivery to the Investor hereunder of such Fixed Purchase Notice, VWAP Purchase Notice, Additional VWAP Purchase Notice, respectively, duly authorized by all necessary corporate action on the part of the Company. The Commitment Shares, when issued to the Investor in accordance with this Agreement, and the Shares, when issued and sold against payment therefor in accordance with this Agreement, shall be validly issued and outstanding, fully paid and non-assessable and free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof, and the Investor shall be entitled to all rights accorded to a holder of Common Stock. As of the date of this Agreement, 5,000,000 shares of Common Stock have been duly authorized and reserved by the Company for issuance and sale by the Company to the Investor as Shares under this Agreement, and 50,000 shares of Common Stock have been duly authorized and reserved by the Company for issuance by the Company to the Investor as Commitment Shares under this Agreement, collectively representing a number of shares equal to 19.99% of the shares of Common Stock issued and outstanding immediately prior to the execution of this Agreement.

 

Section 4.5.           No Conflicts. The execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation of any provision of the Company’s Charter or Bylaws, (ii) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Company is a party or is bound, (iii) create or impose a lien, charge or encumbrance on any property or assets of the Company under any agreement or any commitment to which the Company is a party or by which the Company is bound or to which any of their respective properties or assets is subject, or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree applicable to the Company or by which any property or asset of the Company is bound or affected (including federal and state securities laws and regulations and the rules and regulations of the Trading Market), except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and violations as would not, individually or in the aggregate, have a Material Adverse Effect. Except as specifically contemplated by this Agreement or the Registration Rights Agreement and as required under the Securities Act and any applicable state securities laws, the Company is not required under any federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency (including, without limitation, the Trading Market) in order for it to execute, deliver or perform any of its respective obligations under the Transaction Documents to which it is a party, or to issue the Securities to the Investor in accordance with the terms hereof and thereof (other than such consents, authorizations, orders, filings or registrations as have been obtained or made prior to the Closing Date); provided, however, that, for purposes of the representation made in this sentence, the Company is assuming and relying upon the accuracy of the representations and warranties of the Investor in this Agreement and the compliance by it with its covenants and agreements contained in this Agreement and the Registration Rights Agreement.

 

12

 

 

Section 4.6.           Commission Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants.

 

(a)            The Company has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act) all Commission Documents for the twelve months preceding the date of this Agreement required to be filed by it (the “Filed Commission Documents”). The Company made available to the Investor via EDGAR or otherwise true and complete copies of the Filed Commission Documents prior to the Closing Date. As of its filing date, each Commission Document complied in all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it, and, as of its filing date (or, if amended or superseded by a filing prior to the Closing Date, on the date of such amended or superseded filing). Each Registration Statement, on the date it is filed with the Commission, on the date it is declared effective by the Commission, on each Fixed Purchase Date, each VWAP Purchase Date and each Additional VWAP Purchase Date, shall comply in all material respects with the requirements of the Securities Act (including, without limitation, Rule 415 under the Securities Act) and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading, except that this representation and warranty shall not apply to statements in or omissions from such Registration Statement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. The Prospectus and each Prospectus Supplement required to be filed pursuant to this Agreement or the Registration Rights Agreement after the Closing Date, when taken together, on its date, on each Fixed Purchase Date, each VWAP Purchase Date and each Additional VWAP Purchase Date, shall comply in all material respects with the requirements of the Securities Act (including, without limitation, Rule 424(b) under the Securities Act) and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, except that this representation and warranty shall not apply to statements in or omissions from the Prospectus or any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. Each Commission Document (other than the Initial Prospectus Supplement or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto) to be filed with or furnished to the Commission after the Closing Date and filed as part of or incorporated by reference in the Initial Prospectus Supplement or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto required to be filed pursuant to this Agreement or the Registration Rights Agreement (including, without limitation, the Current Report), when such document is filed with or furnished to the Commission and, if applicable, when such document becomes effective, as the case may be, shall comply in all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it. There are no outstanding or unresolved comments or undertakings in such comment letters received by the Company from the Commission. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Securities Act or the Exchange Act. To the Company’s Knowledge, the Commission has not commenced any enforcement proceedings against the Company.

 

(b)            The financial statements and schedules of the Company to be filed as part of or incorporated by reference in the Initial Prospectus Supplement or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto, present fairly in all material respects the financial condition, results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable accounting requirements of Regulation S-X, and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved (except as otherwise noted therein). The statistical and market-related data included or incorporated by reference in the Commission Documents, the Initial Prospectus Supplement or any New Registration Statement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such source.

 

13

 

 

(c)            The Company has established and maintain disclosure controls and procedures (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act). Except as disclosed in Commission Documents, such disclosure controls and procedures are designed to ensure that material information relating to the Company is made known to the Company’s Chief Executive Officer and its Chief Financial Officer by others within those entities, and such disclosure controls and procedures are effective to perform the functions for which they were established. The Company has established and maintain internal control over financial reporting (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act). Except as disclosed in Commission Documents, such internal control over financial reporting is designed to provide reasonable assurance that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) any significant deficiencies and material weaknesses in the design or operation of internal controls which could adversely affect the Company’s ability to record, process, summarize, and report financial data; and (ii) any fraud, whether or not material, that involves management or other employees who have a role in the Company’s internal controls. Since the date of the most recent evaluation of such disclosure controls and procedures, except as disclosed in Commission Documents, there have been (A) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (B) no significant changes in internal controls or in other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies.

 

(d)            The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations thereunder, which are applicable to it as of the date hereof.

 

(e)            The Company’s accountants are set forth in the Commission Documents and, to the Knowledge of the Company, such accountants are an independent registered public accounting firm as required by the Securities Act.

 

Section 4.7.           Subsidiaries. The Company has no Subsidiaries.

 

Section 4.8.           No Material Adverse Effect or Material Adverse Change, No Undisclosed Liabilities. Except as otherwise disclosed in any Commission Document, since the end of the Company’s most recent audited fiscal year: (i) the Company has not experienced or suffered any Material Adverse Effect, and, to the Company’s Knowledge, there exists no current state of facts, condition or event which would have a Material Adverse Effect; (ii)  the Company has not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (iii) the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and (iv) there has not been any material change in the capital stock, short-term debt or long-term debt of the Company.

 

14

 

 

The Company has no liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s business since September 30, 2023 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

 

Section 4.9.           No Undisclosed Events or Circumstances. No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company or any of its businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws in the Registration Statement or the Prospectus or the Prospectus Supplement, which has not been disclosed or incorporated by reference in the Registration Statement and the Prospectus or the Prospectus Supplement, or (ii) would reasonably be expected to have a Material Adverse Effect.

 

Section 4.10.         Indebtedness. The Form 10-K for the fiscal year ended December 31, 2023 sets forth, as of December 31, 2023, all outstanding secured and unsecured Indebtedness of the Company , or for which the Company has commitments through such date. For the purposes of this Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements, indemnities and other contingent obligations in respect of Indebtedness of others in excess of $100,000, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of $100,000 due under leases required to be capitalized in accordance with GAAP. There is no existing or continuing default or event of default in respect of any Indebtedness of the Company. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to Title 11 of the United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company have any Knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for the relief of debtors. The Company is financially solvent and is generally able to pay its debts as they become due.

 

15

 

 

Section 4.11.        Title to Assets. The Company has good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects except such as are described or incorporated by reference in the Registration Statement and the Prospectus or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company; and any real property and buildings held under lease by the Company is held by it under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere in any material respect with the use made and proposed to be made of such property and buildings by the Company, except as described or incorporated by reference in the Registration Statement and the Prospectus

 

Section 4.12.         Actions Pending. Except as disclosed in Commission Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the Knowledge of the Company, threatened against or affecting the Company or any of the Subsidiaries, or any of their respective officers or directors in their capacities as such, which would reasonably be expected to have a Material Adverse Effect.

 

Section 4.13.        Compliance With Laws. During the 12-month period immediately preceding the date hereof, except as described in the Filed Commission Documents, the Company is and at all times has been in material compliance with all applicable U.S. and foreign statutes, rules, or regulations applicable to the Company (“Applicable Laws”), except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

Section 4.14.        Certain Fees. Except as set forth on Schedule 4.14, no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 4.14 incurred by the Company that may be due or payable in connection with the transactions contemplated by the Transaction Documents other than to the Investor.

 

Section 4.15.        Operation of Business. The Company possesses or has obtained, all licenses, certificates, consents, orders, approvals, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental entity that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as currently conducted, as described or incorporated by reference in the Commission Documents (the “Permits”), except where the failure to possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. The Company has not received any written notice of any proceeding relating to revocation or modification of any such Permit or has any reason to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not, individually or in the aggregate, have a Material Adverse Effect. This Section 4.15 does not relate to environmental matters, such items being the subject of Section 4.16.

 

16

 

 

Section 4.16.        Environmental Compliance. Other than as set forth on Schedule 4.16, to the Knowledge of the Company, the Company is not in violation of any statute, any rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances (collectively, “Environmental Laws”), owns or operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and the Company is not aware of any pending investigation which might lead to such a claim. Other than as set forth or incorporated by reference in the Registration Statement and the Prospectus, there is no judgment, decree, injunction, rule, writ or order of any governmental entity under any Environmental Laws outstanding against the Company which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

Section 4.17.        Material Agreements. Except as set forth in the Commission Documents, the Company is not a party to any written or oral contract, instrument, agreement commitment, obligation, plan or arrangement of the type that would be required to be filed as an exhibit to the Company’s Annual Report on Form 10-K (collectively, “Material Agreements”). Each of the Material Agreements described in the Commission Documents conform in all material respects to the descriptions thereof contained or incorporated by reference therein. Except as set forth in the Commission Documents, the Company has performed in all material respects all the obligations then required to be performed by them under the Material Agreements, have received no notice of default or an event of default by the Company thereunder and are not aware of any basis for the assertion thereof, and neither the Company nor, to the Knowledge of the Company, any other contracting party thereto are in default under any Material Agreement now in effect, the result of which would have a Material Adverse Effect. Except as set forth in the Commission Documents, each of the Material Agreements is in full force and effect, and constitutes a legal, valid and binding obligation enforceable in accordance with its terms against the Company and, to the Knowledge of the Company, each other contracting party thereto, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

 

Section 4.18.        Transactions With Affiliates. Except as disclosed in the Commission Documents, none of the Company’s, officers or directors, , has either directly or indirectly an interest in, or is a party to, any transaction that would be required to be disclosed as a related party transaction pursuant to Item 404 of Regulation S-K promulgated under the Securities Act.

 

Section 4.19.         Intellectual Property Rights. The Company owns or possesses adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted, except as would not reasonably be expected to have a Material Adverse Effect. None of the Company’s material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions thereof, will expire or terminate within two years from the date of this Agreement, except as would not reasonably be expected to have a Material Adverse Effect. The Company has no Knowledge of any infringement by the Company of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or to the Company’s Knowledge, being threatened against, the Company regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement, which would reasonably be expected to have a Material Adverse Effect.

 

17

 

 

Section 4.20.        Use of Proceeds. The proceeds from the sale of the Shares by the Company to the Investor shall be used by the Company in the manner as will be set forth in the Prospectus included in any Registration Statement (and any post-effective amendment thereto) and any Prospectus Supplement thereto filed pursuant to the Registration Rights Agreement.

 

Section 4.21.        Investment Company Act Status. The Company is not required to be registered as, and immediately after receipt of payment for the Shares will not be required to be registered as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

Section 4.22.        Benefit Plans; Labor Matters. Each benefit and compensation plan, agreement, policy and arrangement that is maintained, administered or contributed to by the Company for current or former employees or directors of, or independent contractors with respect to, the Company has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, and the Company has complied in all material respects with all applicable statutes, orders, rules and regulations in regard to such plans, agreements, policies and arrangements. Each stock option granted under any equity incentive plan of the Company (each, a “Stock Plan”) was granted with a per share exercise price no less than the market price per common share on the grant date of such option in accordance with the rules of the Trading Market, and no such grant involved any “back-dating,” “forward-dating” or similar practice with respect to the effective date of such grant; each such option (i) was granted in compliance in all material respects with Applicable Laws and with the applicable Stock Plan(s), (ii) was duly approved by the Company’s Board of Directors, and (iii) has been properly accounted for in the Company’s financial statements and disclosed, to the extent required, in the Company’s filings or submissions with the Commission, and the Trading Market. The Company is not in violation of or has received written notice of any violation with respect to any federal or state law, regulation or rule relating to discrimination in the hiring, termination, promotion, employment or pay of employees, nor any applicable federal or state wages and hours law, nor any state law, regulation or rule precluding the denial of credit due to the neighborhood in which a property is situated, the violation of any of which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. There are no existing or, to the Knowledge of the Company, threatened labor disputes with the employees of the Company that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

Section 4.23.        Taxes.  The Company has filed on a timely basis (including in accordance with any applicable extensions) all material necessary federal, state, local and foreign income and franchise tax returns required to be filed through the date hereof or have properly requested extensions thereof, and have paid all taxes shown as due thereon, and if due and payable, any related or similar assessment, fine or penalty levied against the Company. Except as disclosed in the Commission Documents, no material tax deficiency has been asserted against any such entity, and the Company has no Knowledge of any tax deficiency that is likely to be asserted against any such entity that, individually or in the aggregate, if determined adversely to any such entity, would reasonably be expected to have a Material Adverse Effect. All material tax liabilities are adequately provided for on the books of the Company.

 

18

 

 

Section 4.24.         Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company is engaged, including, but not limited to, insurance covering real and personal property owned or leased by the Company against theft, damage, destruction, environmental liabilities, acts of vandalism, terrorism, earthquakes, flood and all other risks customarily insured against, all of which insurance is in full force and effect. Neither The Company has not been refused any insurance coverage sought or applied for and nor does it have any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect.

 

Section 4.25.        Dilutive Effect. The Company is aware and acknowledges that issuance of the Securities could cause dilution to existing stockholders and could significantly increase the outstanding number of shares of Common Stock. The Company further acknowledges that its obligation to issue the Commitment Shares and to issue the Shares pursuant to the terms of a Fixed Purchase, VWAP Purchase or Additional VWAP Purchase in accordance with this Agreement is, in each case, unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Company.

 

Section 4.26.        Manipulation of Price. The Company has not, and to its Knowledge no Person acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. Neither the Company nor any of its officers, directors or Affiliates will during the term of this Agreement, and, to the Knowledge of the Company, no Person acting on their behalf will during the term of this Agreement, take any of the actions referred to in the immediately preceding sentence.

 

Section 4.27.        Securities Act. Except as set forth in the Disclosure Schedule, the Company has complied and shall comply with all applicable federal and state securities laws in connection with the offer, issuance and sale of the Securities hereunder, including, without limitation, the applicable requirements of the Securities Act. Each Registration Statement, upon filing with the Commission and at the time it is declared effective by the Commission, shall satisfy all of the requirements of the Securities Act to register the resale of the Registrable Securities included therein by the Investor in accordance with the Registration Rights Agreement on a delayed or continuous basis under Rule 415 under the Securities Act at then-prevailing market prices, and not fixed prices. The Company is not, and has not previously been at any time, an issuer identified in, or subject to, Rule 144(i).

 

19

 

 

Section 4.28.        Listing and Maintenance Requirements; DTC Eligibility. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to, or which to its Knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the Commission is currently contemplating terminating such registration. Except as disclosed in the Filed Commission Documents, the Company has not, in the twelve (12) months preceding the date hereof, received any written notice from any Person to the effect that the Company is not in compliance with the listing or maintenance requirements of the Trading Market. Except as disclosed in the Commission Documents, the Company is in compliance with all such listing and maintenance requirements of the Trading Market. The Common Stock is eligible for participation in the DTC book entry system and has shares on deposit at DTC for transferred electronically to third parties via DTC through its DWAC delivery system. The Company has not received notice from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated.

 

Section 4.29.        Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s Charter or the laws of the State of Delaware that is or could become applicable to the Investor as a result of the Investor and the Company fulfilling their respective obligations or exercising their respective rights under the Transaction Documents (as applicable), including, without limitation, as a result of the Company’s issuance of the Securities and the Investor’s ownership of the Securities.

 

Section 4.30.        Foreign Corrupt Practices. Neither the Company, nor to the Knowledge of the Company, any agent or other Person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”).

 

Section 4.31.         Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the Knowledge of the Company, threatened.

 

20

 

 

Section 4.32.         OFAC. Neither the Company nor, to the Knowledge of the Company, any director, officer, agent, employee or Affiliate of the Company (i) is currently subject to any sanctions administered by the U.S. government, including the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”) or the U.S. Department of State, the United Nations Security Council, the European Union, or the United Kingdom (including sanctions administered or controlled by Her Majesty’s Treasury) (collectively, “Sanctions” and such persons, “Sanctioned Persons”) or other relevant sanctions authority, and (ii) will use the proceeds of this offering, directly or indirectly, to fund or facilitate the activities of any Sanctioned Persons or entity or any country, region or territory that is, at the time of such funding or facilitation, subject to Sanctions or any person or entity located in a country, region or territory subject to Sanctions (including any administered or enforced by OFAC or the U.S. Department of State), the United Nations Security Council, the European Union, or the United Kingdom (including sanctions administered or controlled by Her Majesty’s Treasury). Neither the Company nor, to the Knowledge of the Company, any director, officer, agent, employee or Affiliate of the Company, is a Person that is, or is 50% or more owned or otherwise controlled by a Person that is: (i) the subject of any Sanctions; or (ii) located, organized or resident in a country, region or territory that is, or whose government is, the subject of Sanctions that broadly prohibit dealings with that country, region or territory (including at the time of this agreement, Cuba, Iran, North Korea, Syria and Crimea) (collectively, “Sanctioned Countries” and each, a “Sanctioned Country”). The Company has not engaged in any dealings or transactions with or for the benefit of Sanctioned Persons, or with or in a Sanctioned Country, in the preceding 3 years, nor does the Company have any plans to deal or transact with Sanctioned Persons, or with or in Sanctioned Countries.

 

Section 4.33.         Information Technology; Compliance with Data Privacy Laws. To the Company’s Knowledge and as previously disclosed under Commission Documents, (i) there have been no material breaches or violations of (or unauthorized access to) the Company’s information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications and databases (collectively, the “IT Systems”) or any personal, personally identifiable, sensitive, confidential or regulated data (collectively, “Personal Data”) processed or stored by or on behalf of the Company, except for those that have been remedied without material cost or liability or the duty to notify any regulator, nor are there any pending internal investigations of the Company relating to the same and (ii) the Company is presently in compliance in all material respects with all Applicable Laws, statutes and regulations and contractual obligations relating to the privacy and security of IT Systems and Personal Data.

 

Section 4.34.        No Disqualification Events. None of the Company, any of their predecessors, any affiliated issuer, any director, general partner executive officer, other officer of the Company participating in the Transaction contemplated hereby, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company have exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.

 

21

 

 

Section 4.35.         ERISA. Except for the Company’s 401(k) plan for participation by the Company’s employees or as set forth or incorporated by reference in the Registration Statement and the Prospectus, the Company is not a party to an “employee benefit plan,” as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), which: (i) is subject to Title IV of ERISA and (ii) is or was at any time maintained, administered or contributed to by the Company or any of its ERISA Affiliates (as defined hereafter). These plans are referred to collectively herein as the “Employee Plans.” An “ERISA Affiliate” of any person or entity means any other person or entity which, together with that Person or entity, could be treated as a single employer under Section 414(b), (c), (m) or (o) of the Code. Each Employee Plan has been maintained in material compliance with its terms and the requirements of Applicable Law. Except as set forth or incorporated by reference in the Registration Statement and the Prospectus, there is no liability in respect of post-retirement health and medical benefits for retired employees of the Company or any of its ERISA Affiliates, other than medical benefits required to be continued under Applicable Law. No “prohibited transaction” (as defined in either Section 406 of ERISA or Section 4975 of the Code) has occurred with respect to any Employee Plan; and each Employee Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which could cause the loss of such qualification.

 

Section 4.36.        No Other Similar Agreement. Except as disclosed in the Commission Documents, other than the Transaction Documents to which it is a party, the Company is not a party to any agreement that is (or that contains any term, obligation or restriction that is) in effect on the date hereof with any Person, other than the Investor, relating to any “at the market offering,” “equity line of credit” or any other similar continuous offering in which the Company may offer, issue or sell Common Stock or Common Stock Equivalents at a future determined price.

 

Section 4.37.         Acknowledgement Regarding Investor’s Acquisition of Securities. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm’s-length purchaser with respect to this Agreement and the transactions contemplated by the Transaction Documents. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated by the Transaction Documents, and any advice given by the Investor or any of its representatives or agents in connection therewith is merely incidental to the Investor’s acquisition of the Securities. The Company further represents to the Investor that the Company’s decision to enter into the Transaction Documents to which it is a party has been based solely on the independent evaluation of the transactions contemplated thereby by the Company, respectively, and their respective representatives. The Company acknowledges and agrees that the Investor has not made and does not make any representations or warranties with respect to the transactions contemplated by the Transaction Documents other than those specifically set forth in Article IV.

 

Article V
ADDITIONAL COVENANTS

 

The Company covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the benefit of the other party during the Investment Period:

 

Section 5.1.           Securities Compliance. The Company shall notify the Commission and the Trading Market, if and as applicable, in accordance with their respective rules and regulations, of the transactions contemplated by the Transaction Documents, and shall take all necessary action, undertake all proceedings and obtain all registrations, permits, consents and approvals for the legal and valid issuance of the Securities to the Investor in accordance with the terms of the Transaction Documents, as applicable.

 

22

 

 

Section 5.2.           Reservation of Common Stock. The Company has available and the Company shall reserve and keep available at all times, free of preemptive and other similar rights of stockholders, 5,050,000 shares of authorized but unissued shares of Common Stock to enable the Company to time effect the issuance, sale and delivery of all Shares pursuant to this Agreement. As of the date of this Agreement the Company has reserved, and as of the Commencement Date shall have continued to reserve, out of its authorized and unissued Common Stock, 5,000,000 shares of Common Stock solely for the purpose of effecting Fixed Purchases, VWAP Purchases and Additional VWAP Purchases under this Agreement, and 50,000 shares of Common Stock solely for the purpose of issuing the Commitment Shares not payable at the Closing. The number of shares of Common Stock so reserved for the purpose of effecting Fixed Purchases, VWAP Purchases and Additional VWAP Purchases under this Agreement may be increased from time to time by the Company from and after the Commencement Date, and such number of reserved shares may be reduced from and after the Commencement Date only by the number of Shares actually issued, sold and delivered to the Investor pursuant to any Fixed Purchase, VWAP Purchase and Additional VWAP Purchase effected from and after the Commencement Date pursuant to this Agreement.

 

Section 5.3.           Registration and Listing. The Company shall use its commercially reasonable efforts to cause the Common Stock to continue to be registered as a class of securities under Sections 12(b) of the Exchange Act, and to comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities Act or the Exchange Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under the Exchange Act or Securities Act, except as permitted herein. The Company shall use its commercially reasonable efforts to continue the listing and trading of its Common Stock and the listing of the Securities purchased by the Investor hereunder on the Trading Market and to comply with the Company’s reporting, filing and other obligations under the rules and regulations of the Trading Market. The Company shall not take any action which could be reasonably expected to result in the delisting or suspension of the Common Stock on the Trading Market. If the Company receives any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain, the Company shall promptly (and in any case within 24 hours) notify the Investor of such fact in writing and shall use its commercially reasonable efforts to cause the Common Stock to be listed or quoted on another Eligible Market.

 

23

 

 

Section 5.4.           Compliance with Laws.

 

(i)            During the Investment Period, (a) the Company shall comply, with all laws, rules, regulations and orders applicable to the business and operations of the Company, except as would not have a Material Adverse Effect, and (b) the Company shall comply with all applicable provisions of the Securities Act and the Exchange Act, including Regulation M thereunder, applicable state securities or “Blue Sky” laws, and applicable listing rules of the Trading Market or Eligible Market, except as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Company to enter into and perform its obligations under this Agreement in any material respect or for Investor to conduct resales of Securities under the Registration Statement in any material respect. Without limiting the foregoing, none of the Company, nor to the Knowledge of the Company, any of their respective directors, officers, agents, employees or any other Persons acting on their behalf shall, in connection with the operation of the respective businesses of the Company, (1) use any corporate funds for unlawful contributions, payments, gifts or entertainment or to make any unlawful expenditures relating to political activity to government officials, candidates or members of political parties or organizations, (2) pay, accept or receive any unlawful contributions, payments, expenditures or gifts, or (3) violate or operate in noncompliance with any export restrictions, anti-boycott regulations, embargo regulations or other applicable domestic or foreign laws and regulations, including, without limitation, the FCPA and the Money Laundering Laws.

 

(ii)            The Investor shall comply with all laws, rules, regulations and orders applicable to the performance by it of its obligations under this Agreement and its investment in the Securities, except as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect. Without limiting the foregoing, the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act, including Regulation M thereunder, and all applicable state securities or “Blue Sky” laws. Neither the Investor nor any of its officers or directors will take, directly or indirectly, any action designed or intended to cause or to result in, or which would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale of any of the Securities.

 

Section 5.5.           Keeping of Records and Books of Account; Due Diligence.

 

(i)            The Investor and the Company shall each maintain records showing the remaining the remaining Total Purchase Commitment, the remaining Aggregate Limit and the dates and Fixed Purchase Share Amount, VWAP Purchase Share Amount and Additional VWAP Purchase Share Amount for each Fixed Purchase, each VWAP Purchase and each Additional VWAP Purchase, respectively.

 

(ii)            The Investor shall have the right, subject to entering into a confidentiality agreement if applicable, from time to time as the Investor may reasonably deem appropriate, and upon reasonable advance notice to the Company (which such notice shall not be less than five (5) Trading Days), to perform reasonable due diligence on the Company during normal business hours; provided, however, that after the Closing Date, the Investor’s continued due diligence of the Company shall not be a condition precedent to, or otherwise impair, delay or modify in any respect, the Company’s right to deliver to the Investor any Fixed Purchase Notice, any VWAP Purchase Notice and any Additional VWAP Purchase Notice, or the Investor’s obligation to purchase the Shares subject thereto, pursuant to this Agreement. The Company and its officers and employees shall provide information on a reasonably timely basis and otherwise reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor’s due diligence of the Company.

 

24

 

 

Section 5.6.           No Frustration; Prohibition of Certain Issuances Before Settlement of Purchases; No Similar Transactions.

 

(i)             No Frustration. The Company shall not enter into, announce or recommend to the Company’s stockholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents to which it is a party, including, without limitation, the obligation of the Company to deliver (i) the Commitment Shares, not including the Back End Commitment Shares, to the Investor not later than 4:00 p.m. (New York time) on the Trading Day immediately following the Closing Date in accordance with Section 9(ii) of this Agreement, (ii) the Shares to the Investor in respect of a Fixed Purchase as DWAC Shares not later than 4:00 p.m., New York City time, on the Trading Day immediately following the applicable Fixed Purchase Date for such Fixed Purchase in accordance with Section 2.1 of this Agreement, (iii) the Shares to the Investor in respect of a VWAP Purchase as DWAC Shares not later than 4:00 p.m., New York City time, on the Trading Day immediately following the applicable VWAP Purchase Date for such VWAP Purchase in accordance with Section 2.2 of this Agreement, (iv) Shares to the Investor in respect of an Additional VWAP Purchase as DWAC Shares not later than 4:00 p.m., New York City time, on the Trading Day immediately following the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase in accordance with Section 2.3 of this Agreement and (v) the Back End Commitment Shares. For the avoidance of doubt, nothing in this Section 5.6(i) shall in any way limit the Company’s right to terminate this Agreement in accordance with Section 7.2 (subject in all cases to Section 7.3).

 

(ii)            No Dilutive Issuances During Reference Periods. Other than an Exempt Issuance or pursuant to the terms hereof, the Company shall not issue, sell or grant any right, option or warrant to purchase, or issue, sell or grant any right to reprice (or reset the purchase price therefor), or otherwise dispose of for cash (or enter into any agreement, plan or arrangement contemplating any of the foregoing, or seek to utilize any existing agreement, plan or arrangement to effect any of the foregoing), or announce any offer, issuance, sale or grant of any option or warrant to purchase or other disposition for cash (or any agreement, plan or arrangement therefor), at any time during the following periods: (i) with respect to each Fixed Purchase for which the Company has delivered to the Investor a Fixed Purchase Notice, the period beginning on the third (3rd) Trading Day immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase and ending on the third (3rd) Trading Day next following the Trading Day on which the Investor has delivered to the Company the applicable total purchase price for all of the Shares to be purchased by the Investor in such Fixed Purchase pursuant to Section 2.1, and (ii) with respect to each VWAP Purchase and Additional VWAP Purchase under this Agreement for which the Company has delivered to the Investor a VWAP Purchase Notice and (if applicable) an Additional VWAP Purchase Notice, respectively, the period beginning on the third (3rd) Trading Day immediately preceding the applicable VWAP Purchase Date for such VWAP Purchase (and, with respect to each Additional VWAP Purchase effected on the same Trading Day as such VWAP Purchase Date, the applicable Additional VWAP Purchase Date, if any, for such Additional VWAP Purchase) and ending on the third (3rd) Trading Day next following the Trading Day on which the Investor has delivered to the Company the applicable total purchase price for all of the Shares to be purchased by the Investor in such VWAP Purchase, and the applicable total purchase price of all of the Shares to be purchased by the Investor in such Additional VWAP Purchase(s), as applicable, pursuant to Section 2.2 and Section 2.3 (each such period referred to in clause (i) and (ii) above, a “Reference Period”), any Common Stock or Common Stock Equivalents, at an effective price per share of Common Stock less than the applicable Fixed Purchase Price, VWAP Purchase Price or Additional VWAP Purchase Price (as applicable) per Share (such price, the “Reference Price”) to be sold to the Investor in the applicable Fixed Purchase, VWAP Purchase and Additional VWAP Purchase (as applicable) to which such Reference Period relates (each such issuance, a “Dilutive Issuance”), other than an Exempt Issuance or pursuant to the terms hereof (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share of Common Stock that is less than the applicable Reference Price, such issuance shall be deemed to have occurred for less than the applicable Reference Price on such date of the Dilutive Issuance at such effective price) and the applicable Fixed Purchase Price, VWAP Purchase Price or Additional VWAP Purchase Price (as applicable) shall be reduced to equal the Reference Price. If the Company enters into a Variable Rate Transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion or exercise price at which such securities may be converted or exercised. The Investor shall be entitled to seek injunctive relief against the Company to preclude any such Dilutive Issuance that does not constitute an Exempt Issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required.

 

25

 

 

(iii)           No Other Similar Transactions. From and after the date of this Agreement until the termination of this Agreement pursuant to Section 7 (the “Similar Transaction Restricted Period”), none of the Company or any Subsidiary shall issue, sell or grant any, or otherwise dispose of or issue (or enter into any agreement, plan or arrangement contemplating any of the foregoing, or seek to utilize any existing agreement, plan or arrangement to effect any of the foregoing), or announce any offer, issuance, sale or grant or other disposition or issuance of (or any agreement, plan or arrangement therefor) any Common Stock or Common Stock Equivalents (or a combination of units thereof) in any “equity line of credit,” “at the market offering” or other similar continuous offering in which the Company may offer, issue or sell Common Stock or Common Stock Equivalents (or any combination of units thereof) at a future determined price, other than (a) Securities issued to the Investor pursuant to this Agreement and any of the other Transaction Documents or pursuant to any other agreement entered into by the Company and the Investor at any time after the date of this Agreement, and (b) any securities of the Company issued upon the exercise or exchange of or conversion of any shares of Common Stock or Common Stock Equivalents held by the Investor at any time (such similar transaction other than those referred to clauses (a) and (b) hereof, a “Similar Transaction”). From and after the date immediately following the last day of the Similar Transaction Restricted Period, the Company shall be permitted to enter into an agreement, plan or arrangement to effect a Similar Transaction (and may publicly announce the same), and the Company shall be permitted to take all such actions necessary or as contemplated thereby in order to satisfy any conditions required thereunder to be satisfied by the Company in order to commence issuances and sales of Common Stock or Common Stock Equivalents (or a combination of units thereof) thereunder, including, without limitation, preparing and filing with the Commission one or more registration statements to register under the Securities Act the offer, issuance and sale by the Company of Common Stock or Common Stock Equivalents (or a combination of units thereof) thereunder, or to register the resale by any Person or Persons of Common Stock or Common Stock Equivalents (or a combination of units thereof) that may be issued or sold by the Company to such Person or Persons thereunder; provided, however, that the Company may not issue, sell or otherwise dispose of any shares of Common Stock or Common Stock Equivalents (or a combination of units thereof) to or through any Person or Persons thereunder prior to the date of termination of this Agreement pursuant to Section 7. The Investor shall be entitled to seek injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required.

 

26

 

 

Section 5.7.           Corporate Existence. The Company shall take all steps necessary to preserve and continue the corporate existence of the Company; provided, however, that, except as provided in Section 5.8, nothing in this Agreement shall be deemed to prohibit the Company from engaging in any Fundamental Transaction with another Person. For the avoidance of doubt, nothing in this Section 5.7 shall in any way limit the Company’s right to terminate this Agreement in accordance with Section 7.2 (subject in all cases to Section 7.3).

 

Section 5.8.           Fundamental Transaction. If a Fixed Purchase Notice, a VWAP Purchase Notice or an Additional VWAP Purchase Notice has been delivered by the Company to the Investor under Article II and the applicable Fixed Purchase, VWAP Purchase and Additional VWAP Purchase, respectively, has or have not yet been fully settled in accordance with this Agreement (including, without limitation, the delivery by the Investor to the Company of the applicable total purchase price for all of the Shares to be purchased by the Investor in such Fixed Purchase, VWAP Purchase and Additional VWAP Purchase, respectively, as contemplated by Article II), the Company shall not effect any Fundamental Transaction until the expiration of three (3) Trading Days following the Trading Day on which the Investor has delivered to the Company the applicable total purchase price for all of the Shares to be purchased by the Investor in such Fixed Purchase, VWAP Purchase and Additional VWAP Purchase, respectively.

 

Section 5.9.           Selling Restrictions.

 

(i)            Except as expressly set forth below, the Investor covenants that from and after the Closing Date through and including the Trading Day next following the expiration or termination of this Agreement (the “Restricted Period”), neither the Investor nor any of its Affiliates nor any entity managed or controlled by the Investor (collectively, the “Restricted Persons” and each of the foregoing is referred to herein as a “Restricted Person”) shall, directly or indirectly, (x) engage in any Short Sales involving the Company’s securities or (y) grant any option to purchase, or acquire any right to dispose of or otherwise dispose for value of, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for any shares of Common Stock, or enter into any swap, hedge or other similar agreement that transfers, in whole or in part, the economic risk of ownership of the Common Stock. Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during the Restricted Period from: (1) selling “long” (as defined under Rule 200 promulgated under Regulation SHO) the Securities; or (2) selling a number of shares of Common Stock equal to the number of Shares that such Restricted Person is or may be obligated to purchase under a pending Fixed Purchase Notice, a pending VWAP Purchase Notice or a pending Additional VWAP Purchase Notice but has not yet taken possession of so long as such Restricted Person (or the Broker-Dealer, as applicable) delivers the Shares purchased pursuant to such Fixed Purchase Notice, such VWAP Purchase Notice or such Additional VWAP Purchase Notice (as applicable) to the purchaser thereof or the applicable Broker-Dealer upon such Restricted Person’s receipt of such shares of Common Stock from the Company pursuant to this Agreement.

 

27

 

 

(ii)            In addition to the foregoing, in connection with any sale of Securities (including any sale permitted by paragraph (i) above), the Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements of the Securities Act and the Exchange Act.

 

Section 5.10.         Effective Registration Statement. During the Investment Period, the Company shall use its commercially reasonable efforts to maintain the continuous effectiveness of the Initial Prospectus Supplement and each New Registration Statement filed with the Commission under the Securities Act for the applicable Registration Period pursuant to and in accordance with the Registration Rights Agreement.

 

Section 5.11.         Blue Sky. The Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption for or to qualify the Securities for sale by the Company to the Investor pursuant to the Transaction Documents, and at the request of the Investor, the subsequent resale of Registrable Securities by the Investor, in each case, under applicable state securities or “Blue Sky” laws and shall provide evidence of any such action so taken to the Investor from time to time following the Closing Date; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 5.11, (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

 

Section 5.12.        Non-Public Information. Subject to the provisions of Section 5.5(ii) herein, none of the Company, nor any of its directors, officers, employees or agents shall disclose any material non-public information about the Company to the Investor, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the Company, or any of their respective directors, officers, employees and agents (as determined in the reasonable good faith judgment of the Investor), (i) the Investor shall promptly provide written notice of such breach to the Company and (ii) after such notice has been provided to the Company and, provided that the Company shall have failed to publicly disclose such material, non-public information within 24 hours following demand therefor by the Investor, in addition to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval by the Company or any of its directors, officers, employees or agents provided, however, prior to exercising this right, the Investor shall provide the Company with written notice of the Company's alleged failure to disclose such information, which notice shall (i) include a description of the disclosure that the Investor intends to make and (ii) provide the Company with at least one (1) business day to cure such failure (the first business day following such one-business day cure period, the “Cleansing Date”). The Investor shall not have any liability to the Company or any of their respective directors, officers, employees, stockholders or agents, for any such disclosure.

 

28

 

 

Section 5.13.         Broker/Dealer. The Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that it may purchase or otherwise acquire from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be unaffiliated with the Investor and not then currently engaged or used by the Company, and a DTC participant (collectively, the “Broker-Dealer”). The Investor shall, from time to time, provide the Company and the Transfer Agent with all information regarding the Broker-Dealer reasonably requested by the Company. The Investor shall be solely responsible for all fees and commissions of the Broker-Dealer, which shall not exceed customary brokerage fees and commissions and shall be responsible for designating only a DTC participant eligible to receive DWAC Shares.

 

Section 5.14.         Disclosure Schedules.

 

(i)            The Company may, from time to time, update the Disclosure Schedules as may be required to satisfy the conditions set forth in Section 6.2(i) and Section 6.3 (to the extent such condition set forth in Section 6.3 relates to the condition in Section 6.2(i) as of a specific Notice Delivery Time). For purposes of this Section 5.14, any disclosure made in a schedule to the Compliance Certificate shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the contrary, no update to the Disclosure Schedule pursuant to this Section 5.14 shall cure any breach of a representation or warranty of the Company contained in this Agreement and made prior to the update and shall not affect any of the Investor’s rights or remedies with respect thereto.

 

(ii)            Notwithstanding anything to the contrary contained in the Disclosure Schedule or in this Agreement, the information and disclosure contained in any Commission Filing or Schedule of the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Schedule of the Disclosure Schedule as though fully set forth in such Schedule for which applicability of such information and disclosure is reasonably apparent. The fact that any item of information is disclosed in the Disclosure Schedule shall not be construed to mean that such information is required to be disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and the thresholds (whether based on quantity, qualitative characterization, dollar amounts or otherwise) set forth herein shall not be used as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this Agreement.

 

29

 

 

Section 5.15.         Delivery of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events. Within three (3) Trading Days immediately following the (i) filing of (A) a post-effective amendment to the Registration Statement required to be filed by the Company with the Commission pursuant to the Registration Rights Agreement, (B) a New Registration Statement required to be filed by the Company with the Commission pursuant to Section 2(c) of the Registration Rights Agreement, or (C) a post-effective amendment to a New Registration Statement required to be filed by the Company with the Commission pursuant to Section 2(c) of the Registration Rights Agreement, in each case with respect to a fiscal year ending after the Commencement Date, to register the resale of Securities by the Investor under the Securities Act pursuant to this Agreement and the Registration Rights Agreement, and (ii) the date the Company files with the Commission (A) a Prospectus Supplement to the Prospectus contained in the Initial Prospectus Supplement or any New Registration Statement under the Securities Act, (B) an annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date, (C) an amendment on Form 10-K/A to an annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date, which contains amended material financial information (or a restatement of material financial information) or an amendment to other material information contained in a previously filed Form 10-K, and (D) a Commission Document under the Exchange Act (other than those referred to in clauses (ii)(A) and (ii)(B) of this Section 5.15), which contains amended material financial information (or a restatement of material financial information) or an amendment to other material information contained or incorporated by reference in the Initial Prospectus Supplement, any New Registration Statement, or the Prospectus or any Prospectus Supplement contained in the Initial Prospectus Supplement or any New Registration Statement (it being hereby acknowledged and agreed that the filing by the Company with the Commission of a quarterly report on Form 10-Q that includes only updated financial information as of the end of the Company’s most recent fiscal quarter shall not, in and of itself, constitute an “amendment” or “restatement” for purposes of clause (ii) of this Section 5.15), in each case of this clause (ii) if the Company is not also then required under the Securities Act to file a post-effective amendment to the Initial Prospectus Supplement, any New Registration Statement or a post-effective amendment to any New Registration Statement, in each case with respect to a fiscal year ending after the Commencement Date, to register the resale of Securities by the Investor under the Securities Act pursuant to this Agreement and the Registration Rights Agreement, and in any case of this clause (ii), not more than once per calendar quarter, the Company shall (I) deliver to the Investor a Compliance Certificate, dated such date, and (II) cause to be furnished to the Investor an opinion “bring down” from outside counsel to the Company substantially in the form mutually agreed to by the Company and the Investor prior to the date of this Agreement, modified, as necessary, to relate to such Registration Statement or post-effective amendment, or the Prospectus contained therein as then amended or supplemented by such Prospectus Supplement, as applicable (each such opinion, a “Bring Down Opinion”).

 

Article VI
CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND
PURCHASE OF THE SHARES

 

Section 6.1.           Conditions Precedent to Closing. The Closing is subject to the satisfaction of each of the conditions set forth in this Section 6.1 on the Closing Date.

 

(i)             Accuracy of the Investor’s Representations and Warranties. The representations and warranties of the Investor contained in this Agreement (a) that are not qualified by “materiality” shall be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by “materiality” shall be true and correct as of the Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other date.

 

30

 

 

(ii)            Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company contained in this Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by “materiality” or “Material Adverse Effect” shall be true and correct as of the Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other date.

 

(iii)           Issuance of Commitment Shares. On the Closing Date, the Company shall deliver irrevocable instructions to the Transfer Agent to issue to the Investor, not later than 4:00 p.m. (New York City time) on the Closing Date, as DWAC Shares, the Initial Commitment Shares, in consideration for the Investor’s execution and delivery of this Agreement.

 

(iv)           Closing Deliverables. At the Closing, counterpart signature pages of this Agreement and the Registration Rights Agreement executed by each of the parties hereto shall be delivered as provided in Section 1.2. Simultaneously with the execution and delivery of this Agreement and the Registration Rights Agreement, the Investor’s counsel shall have received (a) the closing certificate from the Company, dated as of the Closing Date, in the form of Exhibit B hereto, and (b) a copy of the irrevocable instructions to the Transfer Agent regarding the issuance to the Investor or its designee of the Initial Commitment Shares, pursuant to and in accordance with Section 9.1(ii) hereof.

 

Section 6.2.           Conditions Precedent to Commencement. The right of the Company to commence delivering Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices under this Agreement, and the obligation of the Investor to accept Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices delivered to the Investor by the Company under this Agreement, are subject to the initial satisfaction, at the time of Commencement, of each of the conditions set forth in this Section 6.2.

 

(i)            Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company contained in this Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the Commencement Date with the same force and effect as if made on such date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by “materiality” or “Material Adverse Effect” shall have been true and correct when made and shall be true and correct as of the Commencement Date with the same force and effect as if made on such date, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other date.

 

(ii)           Performance of the Company. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by the Company at or prior to the Commencement. The Company shall deliver to the Investor on the Commencement Date the compliance certificate substantially in the form attached hereto as Exhibit C (the “Compliance Certificate”).

 

31

 

 

(iii)           Shelf Registration Statement Effective. The Shelf Registration Statement shall continue to be effective under the Securities Act. The Initial Prospectus Supplement each shall have been filed with the SEC, as required pursuant to Section 1.3.

 

(iv)          No Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or any other federal or state governmental authority for any additional information relating to the Initial Prospectus Supplement, or the Prospectus contained therein or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Prospectus Supplement, the Prospectus contained therein or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Prospectus Supplement or prohibiting or suspending the use of the Prospectus contained therein or any Prospectus Supplement thereto, or of the suspension of qualification or exemption from qualification of the Securities for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; or (c) the occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact made in the Initial Prospectus Supplement, the Prospectus contained therein or any Prospectus Supplement thereto untrue or which requires the making of any additions to or changes to the statements then made in the Initial Prospectus Supplement, the Prospectus contained therein or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances under which they were made) not misleading, or which requires an amendment to the Initial Prospectus Supplement or a supplement to the Prospectus contained therein or any Prospectus Supplement thereto to comply with the Securities Act or any other law. The Company shall not have any Knowledge of any event that would reasonably be expected to have the effect of causing the suspension of the effectiveness of the Initial Prospectus Supplement or the prohibition or suspension of the use of the Prospectus contained therein or any Prospectus Supplement thereto in connection with the resale of the Registrable Securities by the Investor.

 

(v)            Other Commission Filings. The Current Report shall have been filed with the Commission as required pursuant to Section 1.3. The final Prospectus included in any post-effective amendment to the Initial Prospectus Supplement, and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 1.3 and the Registration Rights Agreement after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission in accordance with Section 1.3 and the Registration Rights Agreement. The final Prospectus included in any New Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 1.3 and the Registration Rights Agreement after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission in accordance with Section 1.3 and the Registration Rights Agreement. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission and, if any Registrable Securities are covered by a Registration Statement on Form S-3, such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act.

 

32

 

 

(vi)          No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the Commission, the Trading Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the Commencement Date), the Company shall not have received any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have been imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension or restriction).

 

(vii)         Compliance with Laws. The Company shall have complied in all material respects with all applicable federal, state and local governmental laws, rules, regulations and ordinances in connection with the execution, delivery and performance of this Agreement and the other Transaction Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby, including, without limitation, the Company shall have obtained all permits and qualifications required by any applicable state securities or “Blue Sky” laws for the offer and sale of the Securities by the Company to the Investor and the subsequent resale of the Registrable Securities by the Investor (or shall have the availability of exemptions therefrom).

 

(viii)        No Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of, or which would materially modify or delay any of the transactions contemplated by, the Transaction Documents.

 

(ix)           No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have been commenced, and no inquiry or investigation by any governmental authority shall have been commenced, against the Company or any of the officers, directors or Affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking material damages in connection with such transactions.

 

(x)            Listing of Securities. All of the Securities that have been and may be issued pursuant to this Agreement shall have been approved for listing or quotation on the Trading Market as of the Commencement Date, subject only to notice of issuance.

 

33

 

 

(xi)           No Material Adverse Effect. No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall have occurred and be continuing.

 

(xii)          No Bankruptcy Proceedings. No Person shall have commenced a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law. The Company shall not have, pursuant to or within the meaning of any Bankruptcy Law, (a) commenced a voluntary case, (b) consented to the entry of an order for relief against it in an involuntary case, (c) consented to the appointment of a Custodian of the Company for all or substantially all of the Company’s property, or (d) made a general assignment for the benefit of its creditors. A court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (I) is for relief against the Company in an involuntary case, (II) appoints a Custodian of the Company for all or substantially all of the Company’s property, or (III) orders the liquidation of the Company.

 

(xiii)         Commitment Shares Issued as DWAC Shares. Following the filing of the Prospectus Supplement, and in no event later than three (3) Trading Days following the date hereof, the Company shall have caused the Transfer Agent to credit the Investor’s or its designee’s account at DTC as DWAC Shares such number of shares of Common Stock equal to the Initial Commitment Shares, not including the Back End Commitment Shares, issued pursuant to Section 9.1(ii) hereof.

 

(xiv)         Delivery of Commencement Irrevocable Transfer Agent Instructions and Notice of Effectiveness. The Commencement Irrevocable Transfer Agent Instructions shall have been executed by the Company and delivered to acknowledged in writing by the Transfer Agent, and the Notice of Effectiveness relating to the Initial Prospectus Supplement shall have been executed by the Company’s outside counsel and delivered to the Transfer Agent, in each case directing the Transfer Agent to issue to the Investor or its designated Broker-Dealer all of the Commitment Shares, not including the Back End Commitment Shares, and Shares included in the Initial Prospectus Supplement as DWAC Shares in accordance with this Agreement and the Registration Rights Agreement.

 

(xv)         Reservation of Shares. As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock, ____________ shares of Common Stock solely for the purpose of effecting Fixed Purchases, VWAP Purchases, and Additional VWAP Purchases, and Back End Commitment Shares under this Agreement.

 

(xvi)         Opinions of Company Counsel. On the Commencement Date, the Investor shall have received the opinion and negative assurances from outside counsel to the Company, dated the Commencement Date, in the forms mutually agreed to by the Company and the Investor prior to the date of this Agreement.

 

34

 

 

Section 6.3.           Conditions Precedent to Purchases by Investor. The right of the Company to deliver Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices under this Agreement after the Commencement Date, and the obligation of the Investor to accept Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices under this Agreement after the Commencement Date, are subject to the satisfaction of each of the conditions set forth in this Section 6.3: (i) with respect to each Fixed Purchase after the Commencement Date, at the time of delivery of the applicable Fixed Purchase Notice to the Investor on the applicable Fixed Purchase Date for such Fixed Purchase, (ii) with respect to each VWAP Purchase after the Commencement Date, (A) at the time of delivery of the applicable VWAP Purchase Notice to the Investor and (B) immediately prior to the applicable VWAP Purchase Commencement Time on the applicable VWAP Purchase Date for such VWAP Purchase, and (iii) with respect to each Additional VWAP Purchase after the Commencement Date, (A) at the time of delivery of the applicable Additional VWAP Purchase Notice to the Investor and (B) immediately prior to the applicable Additional VWAP Purchase Commencement Time on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (each such time referred to in clauses (i), (ii) and (iii) hereof, a “Notice Delivery Time”).

 

(i)            Satisfaction of Certain Prior Conditions. Each of the conditions set forth in subsections (i), (ii), and (vii) through (xv) set forth in Section 6.2 shall be satisfied at the applicable Notice Delivery Time after the Commencement Date (with the terms “Commencement” and “Commencement Date” in the conditions set forth in subsections (i) and (ii) of Section 6.2 replaced with “applicable Notice Delivery Time”); provided, however, that the Company shall not be required to deliver the Compliance Certificate after the Commencement Date, except as provided in Section 5.1 and Section 6.2(ii).

 

(ii)            Shelf Registration Statement Effective. The Shelf Registration Statement covering the registration of the Registrable Securities, and any post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date and prior to the applicable Fixed Purchase Date, the applicable VWAP Purchase Date and the applicable Additional VWAP Purchase Date, pursuant to the Registration Rights Agreement, in each case shall remain effective, and the Investor shall be permitted and able to utilize the Initial Prospectus Supplement, to resell (a) all of the Commitment Shares, (b) all of the Shares included in the Initial Prospectus Supplement, and any post-effective amendment thereto, that have been issued and sold to the Investor hereunder pursuant to all Fixed Purchase Notices, all VWAP Purchase Notices and all Additional VWAP Purchase Notices (as applicable) delivered by the Company to the Investor prior to such applicable Fixed Purchase Date, such applicable VWAP Purchase Date and such Additional VWAP Purchase Date, respectively, and (c) all of the Shares included in the Initial Prospectus Supplement, and any post-effective amendment thereto, that are issuable pursuant to the applicable Fixed Purchase Notice, the applicable VWAP Purchase Notice and the applicable Additional VWAP Purchase Notice (as applicable) delivered by the Company to the Investor with respect to a Fixed Purchase, a VWAP Purchase and an Additional VWAP Purchase, respectively, to be effected hereunder on such applicable Fixed Purchase Date, such applicable VWAP Purchase Date and such applicable Additional VWAP Purchase Date, respectively.

 

35

 

 

(iii)           Any Required New Registration Statement Effective. Any New Registration Statement covering the resale by the Investor of the Registrable Securities, included therein, and any post-effective amendment thereto, required to be filed by the Company with the Commission pursuant to the Registration Rights Agreement after the Commencement Date and prior to the applicable Fixed Purchase Date, the applicable VWAP Purchase Date and the applicable Additional VWAP Purchase Date (as applicable), in each case shall have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable Registration Period, and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto, to resell (a) all of the then-issued Commitment Shares (if any) included in such New Registration Statement, and any post-effective amendment thereto, (b) all of the Shares included in such New Registration Statement, and any post-effective amendment thereto, that have been issued and sold to the Investor hereunder pursuant to all Fixed Purchase Notices, all VWAP Purchase Notices and all Additional VWAP Purchase Notices (as applicable) delivered by the Company to the Investor prior to such applicable Fixed Purchase Date, such applicable VWAP Purchase Date, and such applicable Additional VWAP Purchase Date, respectively, and (c) all of the Shares included in such new Registration Statement, and any post-effective amendment thereto, that are issuable pursuant to the applicable Fixed Purchase Notice, the applicable VWAP Purchase Notice, and the applicable Additional VWAP Purchase Notice (as applicable) delivered by the Company to the Investor with respect to a Fixed Purchase, a VWAP Purchase, and an Additional VWAP Purchase, respectively, to be effected hereunder on such applicable Fixed Purchase Date, such applicable VWAP Purchase Date, and such Additional VWAP Purchase Date, respectively.

 

(iv)          Delivery of Subsequent Irrevocable Transfer Agent Instructions and Notice of Effectiveness. With respect to any post-effective amendment to the Initial Prospectus Supplement, any New Registration Statement or any post-effective amendment to any New Registration Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall have delivered or caused to be delivered to the Transfer Agent (a) irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions executed by the Company and acknowledged in writing by the Transfer Agent and (b) the Notice of Effectiveness, in each case modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities included therein, to issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this Agreement and the Registration Rights Agreement.

 

(v)           No Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or any other federal or state governmental authority for any additional information relating to the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or prohibiting or suspending the use of the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto, or of the suspension of qualification or exemption from qualification of the Securities for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; or (c) the occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact made in the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto untrue or which requires the making of any additions to or changes to the statements then made in the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances under which they were made) not misleading, or which requires an amendment to the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto to comply with the Securities Act or any other law (other than the transactions contemplated by the applicable Fixed Purchase Notice, the applicable VWAP Purchase Notice, and the applicable Additional VWAP Purchase Notice (as applicable) delivered by the Company to the Investor with respect to a Fixed Purchase, a VWAP Purchase, and an Additional VWAP Purchase, respectively, to be effected hereunder on such applicable Fixed Purchase Date, such applicable VWAP Purchase Date, and such applicable Additional VWAP Purchase Date, respectively, and the settlement thereof). The Company shall not have any Knowledge of any event that would reasonably be expected to have the effect of causing the suspension of the effectiveness of the Initial Prospectus Supplement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the prohibition or suspension of the use of the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto in connection with the resale of the Registrable Securities by the Investor.

 

36

 

 

(vi)          Other Commission Filings. The final Prospectus included in any post-effective amendment to the Initial Prospectus Supplement, and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 1.3 and the Registration Rights Agreement after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission in accordance with Section 1.3 and the Registration Rights Agreement. The final Prospectus included in any New Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 1.3 Section 1.3and the Registration Rights Agreement after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission in accordance with Section 1.3 and the Registration Rights Agreement. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, after the Commencement Date and prior to the applicable Fixed Purchase Date and the applicable VWAP Purchase Date and Additional VWAP Purchase Date (as applicable), shall have been filed with the Commission and, if any Registrable Securities are covered by a Registration Statement on Form S-3, such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act.

 

(vii)         No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the Commission, the Trading Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Fixed Purchase Date, VWAP Purchase Date or Additional VWAP Purchase Date, as applicable), the Company shall not have received any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have been imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension or restriction).

 

37

 

 

(viii)        Certain Limitations. The issuance and sale of the Shares issuable pursuant to the applicable Fixed Purchase Notice, applicable VWAP Purchase Notice, and applicable Additional VWAP Purchase Notice (as applicable) shall not (a) exceed the applicable Fixed Purchase Maximum Amount, the applicable VWAP Purchase Maximum Amount and the applicable Additional VWAP Purchase Maximum Amount, respectively, or (b) cause the Aggregate Limit or the Beneficial Ownership Limitation to be exceeded.

 

(ix)           Shares Authorized and Delivered. All of the Shares issuable pursuant to the applicable Fixed Purchase Notice, the applicable VWAP Purchase Notice, and the applicable Additional VWAP Purchase Notice (as applicable) shall have been duly authorized by all necessary corporate action of the Company. All Shares relating to all prior Fixed Purchase Notices, VWAP Purchase Notices, and Additional VWAP Purchase Notices required to have been received by the Investor as DWAC Shares under this Agreement prior to the applicable Notice Delivery Time for the applicable Fixed Purchase, applicable VWAP Purchase and applicable Additional VWAP Purchase (as applicable) shall have been delivered to the Investor as DWAC Shares in accordance with this Agreement.

 

(x)            Bring Down Opinions of Company Counsel. The Investor shall have received (a) all Bring Down Opinions from outside counsel to the Company for which the Company was obligated to instruct their outside counsel to deliver to the Investor prior to the applicable Notice Delivery Time for the applicable Fixed Purchase, applicable VWAP Purchase, and applicable Additional VWAP Purchase (as applicable) and (b) all Compliance Certificates from the Company that the Company was obligated to deliver to the Investor prior to the applicable Notice Delivery Time for the applicable Fixed Purchase, applicable VWAP Purchase and applicable Additional VWAP Purchase (as applicable), in each case in accordance with Section 5.15.

 

38

 

 

Article VII
TERMINATION

 

Section 7.1.           Automatic Termination; Termination by Consent. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically, without any further action or notice by any Person, on the earliest to occur of (i) the expiration of the Registration Statement pursuant to Rule 415(a)(5) of the Securities Act, (ii) the date on which the Investor shall have purchased the Aggregate Limit of Shares pursuant to this Agreement, (iii) the date on which the Common Stock shall have failed to be listed or quoted on the Trading Market or any Eligible Market, (iv) the thirtieth (30th) Trading Day next following the date on which, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, in each case that is not discharged or dismissed prior to such thirtieth (30th) Trading Day, and (v) the date on which, pursuant to or within the meaning of any Bankruptcy Law, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors. Subject to Section 7.3, this Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent.

 

Section 7.2.           Other Termination. Subject to Section 7.3, the Company may terminate this Agreement after the Commencement Date effective upon one (1) Trading Day’s prior written notice to the Investor in accordance with Section 9.4; provided, however, that (i) the Company shall have issued all applicable Commitment Shares to the Investor and paid the Investor Expense Reimbursement s tprior to such termination, and (ii) prior to issuing any press release, or making any public statement or announcement, with respect to such termination, the Company shall consult with the Investor and its counsel on the form and substance of such press release or other disclosure, which consent shall not be unreasonably delayed or withheld. Subject to Section 7.3, this Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent. Subject to Section 7.3, the Investor shall have the right to terminate this Agreement effective upon ten (10) Trading Days’ prior written notice to the Company in accordance with Section 9.4, if: (a) any condition, occurrence, state of facts or event constituting a Material Adverse Effect has occurred and is continuing; (b) a Fundamental Transaction shall have occurred; (c) the Initial Prospectus Supplement and any New Registration Statement is not filed by the applicable Filing Deadline therefor or declared effective by the Commission by the applicable Effectiveness Deadline (as defined in the Registration Rights Agreement) therefor, or the Company is otherwise in breach or default in any material respect under any of the other provisions of the Registration Rights Agreement, and, if such failure, breach or default is capable of being cured, such failure, breach or default is not cured within 10 Trading Days after notice of such failure, breach or default is delivered to the Company pursuant to Section 9.4; (d) while a Registration Statement, or any post-effective amendment thereto, is required to be maintained effective pursuant to the terms of the Registration Rights Agreement and the Investor holds any Registrable Securities, the effectiveness of such Registration Statement, or any post-effective amendment thereto, lapses for any reason (including, without limitation, the issuance of a stop order by the Commission) or such Registration Statement or any post-effective amendment thereto, the Prospectus contained therein or any Prospectus Supplement thereto otherwise becomes unavailable to the Investor for the resale of all of the Registrable Securities included therein in accordance with the terms of the Registration Rights Agreement, and such lapse or unavailability continues for a period of 20 consecutive Trading Days, other than due to acts of the Investor; (e) trading in the Common Stock on the Trading Market (or if the Common Stock is then listed on an Eligible Market, trading in the Common Stock on such Eligible Market) shall have been suspended and such suspension continues for a period of three (3) consecutive Trading Days; or (f) the Company is in material breach or default of this Agreement, and, if such breach or default is capable of being cured, such breach or default is not cured within 10 Trading Days after notice of such breach or default is delivered to the Company (as applicable) pursuant to Section 9.4. Unless notification thereof is required elsewhere in this Agreement (in which case such notification shall be provided in accordance with such other provision), the Company shall promptly (but in no event later than 24 hours) notify the Investor (and, if required under Applicable Law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules and regulations of the Trading Market (or if the Common Stock is then listed on an Eligible Market, the rules and regulations of such Eligible Market), the Company shall publicly disclose such information in accordance with Regulation FD and the applicable rules and regulations of the Trading Market, or the applicable rules and regulations of such Eligible Market, as applicable) upon becoming aware of any of the events set forth in the immediately preceding sentence.

 

39

 

 

Section 7.3.           Effect of Termination. In the event of termination by the Company or the Investor (other than by mutual termination) pursuant to Section 7.2, written notice thereof shall forthwith be given to the other party as provided in Section 9.4 and the transactions contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as provided in Section 7.1 or Section 7.2, this Agreement shall become void and of no further force and effect, except that (i) the provisions of Article VIII (Indemnification) and this Article VII (Termination) shall remain in full force and effect indefinitely notwithstanding such termination, and, (ii) so long as the Investor owns any Securities, the covenants and agreements of the Company contained in Article V (Covenants) shall remain in full force and notwithstanding such termination for a period of thirty days (30) days following such termination. Notwithstanding anything in this Agreement to the contrary, no termination of this Agreement by any party shall (i) become effective prior to the first Trading Day immediately following the settlement date related to any pending Fixed Purchase Notice, any pending VWAP Purchase Notice, or any pending Additional VWAP Purchase Notice (as applicable) that has not been fully settled in accordance with the terms and conditions of this Agreement (it being hereby acknowledged and agreed that no termination of this Agreement shall limit, alter, modify, change or otherwise affect any of the parties’ respective rights or obligations under the Transaction Documents with respect to any pending Fixed Purchase, pending VWAP Purchase, and pending Additional VWAP Purchase (as applicable), and that the parties shall fully perform their respective obligations with respect to any such pending Fixed Purchase, any such pending VWAP Purchase, and any such pending Additional VWAP Purchase (as applicable) under the Transaction Documents, provided all of the conditions to the settlement thereof set forth in Article VI are timely satisfied), (ii) limit, alter, modify, change or otherwise affect the parties’ respective rights or obligations under the Registration Rights Agreement, all of which shall survive any such termination, (iii) affect the Investor Expense Reimbursement paid to the Investor, all of which shall be non-refundable when paid as of the Closing Date pursuant to Section 9.1(i), regardless of whether any Fixed Purchases, VWAP Purchases, or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement, or (iv) affect any Commitment Shares previously issued or delivered, or any rights of any holder thereof, it being hereby acknowledged and agreed that all of the Commitment Shares shall be fully earned as of the Closing Date, regardless of whether any Fixed Purchases, VWAP Purchases or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement. Nothing in this Section 7.3 shall be deemed to release the Company or the Investor from any liability for any breach or default under this Agreement or any of the other Transaction Documents to which it is a party, or to impair the respective rights of the Company and the Investor to compel specific performance by the other party of its obligations under the Transaction Documents to which it is a party.

 

40

 

 

Article VIII
INDEMNIFICATION

 

Section 8.1.           Indemnification of Investor. In consideration of the Investor’s execution and delivery of this Agreement and acquiring the Securities hereunder and in addition to all of the other respective obligations of the Company under the Transaction Documents to which it is a party, subject to the provisions of this Section 8.1(a), the Company shall indemnify and hold harmless the Investor, each of its directors, officers, shareholders, members, partners, employees, representatives, agents and advisors (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title), each Person, if any, who controls the Investor (within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act), and the respective directors, officers, shareholders, members, partners, employees, representatives, agents and advisors (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons (each, an “Investor Party”), from and against all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses (including all judgments, amounts paid in settlement, court costs, reasonable attorneys’ fees and costs of defense and investigation) (collectively, “Damages”) that any Investor Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents to which it is a party or (b) any action, suit, claim or proceeding (including for these purposes a derivative action brought on behalf of the Company) instituted against such Investor Party arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents, other than claims for indemnification within the scope of Section 6 of the Registration Rights Agreement; provided, however, that (x) the foregoing indemnity shall not apply to any Damages to the extent, but only to the extent, that such Damages resulted directly and primarily from any acts or failures to act, undertaken or omitted to be taken by such Investor Party through its fraud, bad faith, gross negligence, or willful or reckless misconduct. Provided further, the Company shall not be liable under this Section 8.1(a) to the extent that a court of competent jurisdiction shall have determined by a final judgment (from which no further appeals are available) that such loss, claim, damage, liability or expense resulted directly and solely from any such acts or failures to act, undertaken or omitted to be taken by the Investor or such Person through its gross negligence or willful misconduct, (B) the foregoing indemnity shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor expressly for use in the Current Report or any Prospectus Supplement or Permitted Free Writing Prospectus, or any amendment thereof or supplement thereto, and (C) with respect to the Prospectus, the foregoing indemnity shall not inure to the benefit of the Investor or any such Person from whom the Person asserting any loss, claim, damage, liability or expense purchased Common Stock, if copies of all Prospectus Supplements required to be filed pursuant to Section 1.3, together with the Base Prospectus, were timely delivered or made available to the Investor pursuant hereto and a copy of the Base Prospectus, together with a Prospectus Supplement (as applicable), was not sent or given by or on behalf of the Investor or any such Person to such Person, if required by law to have been delivered, at or prior to the written confirmation of the sale of the Common Stock to such Person, and if delivery of the Base Prospectus, together with a Prospectus Supplement (as applicable), would have cured the defect giving rise to such loss, claim, damage, liability or expense.

 

41

 

 

The Company shall reimburse any Investor Party promptly upon demand (with accompanying presentation of documentary evidence) for all legal and other costs and expenses reasonably incurred by such Investor Party in connection with (i) any action, suit, claim or proceeding, whether at law or in equity, to enforce compliance by the Company with any provision of the Transaction Documents to which it is a party or (ii) any other any action, suit, claim or proceeding, whether at law or in equity, with respect to which it is entitled to indemnification under this Section 8.1; provided that the Investor shall promptly reimburse the Company for all such legal and other costs and expenses to the extent a court of competent jurisdiction determines that any Investor Party was not entitled to such reimbursement.

 

An Investor Party’s right to indemnification or other remedies based upon the representations, warranties, covenants and agreements of the Company set forth in the Transaction Documents to which it is a party shall not in any way be affected by any investigation or knowledge of such Investor Party. Such representations, warranties, covenants and agreements shall not be affected or deemed waived by reason of the fact that an Investor Party knew or should have known that any representation or warranty might be inaccurate or that the Company failed to comply with any agreement or covenant. Any investigation by such Investor Party shall be for its own protection only and shall not affect or impair any right or remedy hereunder.

 

To the extent that the undertakings by the Company set forth in this Section 8.1(a) may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Damages which is permissible under Applicable Law.

 

Section 8.2.           Indemnification Procedures. Promptly after an Investor Party receives notice of a claim or the commencement of an action for which the Investor Party intends to seek indemnification under Section 8.1, the Investor Party will notify the Company in writing of the claim or commencement of the action, suit or proceeding; provided, however, that failure to notify the Company will not relieve the Company from liability under Section 8.1, except to the extent it has been materially prejudiced by the failure to give notice. The Company will be entitled to participate in the defense of any claim, action, suit or proceeding as to which indemnification is being sought, and if the Company acknowledges in writing the obligation to indemnify the Investor Party against whom the claim or action is brought, the Company may (but will not be required to) assume the defense against the claim, action, suit or proceeding with counsel satisfactory to it. After the Company notifies the Investor Party that the Company wishes to assume the defense of a claim, action, suit or proceeding, the Company will not be liable for any further legal or other expenses incurred by the Investor Party in connection with the defense against the claim, action, suit or proceeding except that if, in the opinion of counsel to the Investor Party, it would be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Company and such Investor Party. In such event, the Company will pay the reasonable fees and expenses of no more than one separate counsel for all such Investor Parties promptly as such fees and expenses are incurred. Each Investor Party, as a condition to receiving indemnification as provided in Section 8.1, will cooperate in all reasonable respects with the Company in the defense of any action or claim as to which indemnification is sought. The Company will not be liable for any settlement of any action effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. The Company will not, without the prior written consent of the Investor Party, effect any settlement of a pending or threatened action with respect to which an Investor Party is, or is informed that it may be, made a party and for which it would be entitled to indemnification, unless the settlement includes an unconditional release of the Investor Party from all liability and claims which are the subject matter of the pending or threatened action.

 

42

 

 

The remedies provided for in this Article VIII are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Investor Party at law or in equity.

 

Article IX
MISCELLANEOUS

 

Section 9.1.           Certain Fees and Expenses; Commitment Shares; Commencement Irrevocable Transfer Agent Instructions.

 

(i)             Certain Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement; provided, however, that immediately following the execution of this Agreement, the Company shall pay, by wire transfer of immediately available funds to an account designated by the Investor, an amount equal to $25,000 to be applied against the Investor’s reasonable out-of-pocket expenses, including the legal fees and disbursements of the Investor’s legal counsel, incurred by the Investor in connection with the preparation, negotiation, execution and delivery of the Transaction Documents by the Investor and its due diligence investigation of the Company (such amount, the “Investor Expense Reimbursement”). For the avoidance of doubt, the Investor Expense Reimbursement, shall be non-refundable when paid as of the Closing Date, regardless of whether any Fixed Purchases, VWAP Purchases or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement and the Company shall have no obligation to make any additional payments. The Company shall pay all U.S. federal, state and local stamp and other similar transfer and other taxes and duties levied in connection with issuance of the Securities pursuant hereto.

 

(ii)            Commitment Shares. In consideration for the Investor’s execution and delivery of this Agreement, concurrently with the execution and delivery of this Agreement on the Closing Date, the Company shall deliver irrevocable instructions to the Transfer Agent to issue to the Investor, not later than 4:00 p.m. (New York City time) on the Trading Day immediately following the Closing Date, the Initial Commitment Shares. Upon issuance, the Initial Commitment Shares shall constitute “restricted securities” as such term is defined in Rule 144(a)(3) under the Securities Act. On the ninetieth (90) calendar day following the Closing Date, the Company shall deliver irrevocable instructions to the Transfer Agent to issue to the Investor, not later than 4:00 p.m. (New York City time) on such date, as DWAC Shares, such that they are credited to the Investor’s or its designee’s specified DWAC account with DTC under its FAST Program, the First Back End Commitment Shares. On the one hundred and eightieth (180) calendar day following the Closing Date, the Company shall deliver irrevocable instructions to the Transfer Agent to issue to the Investor, not later than 4:00 p.m. (New York City time) on such date, as DWAC Shares, such that they are credited to the Investor’s or its designee’s specified DWAC account with DTC under its FAST Program, the Second Back End Commitment Shares (provided that the number of First Back End Commitment Shares and Second Back End Commitment Shares shall not exceed _______ in the aggregate), For the avoidance of doubt, all of the Commitment Shares shall be fully earned as of the Closing Date, whether any Fixed Purchases, VWAP Purchases or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement. The Commitment Shares shall constitute Registrable Securities and shall be included in the New Registration Statement and any post-effective amendment thereto, and the Prospectus included therein and, if necessary to register the resale thereof by the Investor under the Securities Act, in any New Registration Statement and any post-effective amendment thereto, in each case in accordance with this Agreement and the Registration Rights Agreement.

 

43

 

 

(iii)           Irrevocable Transfer Agent Instructions; Notice of Effectiveness. On the Commencement Date, the Company shall cause the Transfer Agent to credit the Investor’s or its designee’s account at DTC as DWAC Shares such number of shares of Common Stock equal to the number of Initial Commitment Shares issued to the Investor pursuant to Section 9.1(ii). The Company shall take all actions to carry out the intent and accomplish the purposes of the immediately preceding sentence, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Transfer Agent, and any successor transfer agent of the Company, as may be requested from time to time by the Investor or necessary or desirable to carry out the intent and accomplish the purposes of the immediately preceding sentence. Upon the filing of the Initial Prospectus Supplement, the Company shall deliver or cause to be delivered to the Transfer Agent (and thereafter, shall deliver or cause to be delivered to any subsequent transfer agent of the Company), (i) irrevocable instructions executed by the Company and acknowledged in writing by the Transfer Agent (the “Commencement Irrevocable Transfer Agent Instructions”) and (ii) the notice of effectiveness in the form attached as an exhibit to the Registration Rights Agreement (the “Notice of Effectiveness”) relating to the Initial Prospectus Supplement executed by the Company, in each case directing the Transfer Agent to issue to the Investor or its designee all of the Commitment Shares as DWAC Shares in accordance with this Agreement and the Registration Rights Agreement. With respect to any post-effective amendment to the Initial Prospectus Supplement, any New Registration Statement or any post-effective amendment to any New Registration Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall deliver or cause to be delivered to the Transfer Agent (and thereafter, shall deliver or cause to be delivered to any subsequent transfer agent of the Company) (i) irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions executed by the Company and acknowledged in writing by the Transfer Agent and (ii) the Notice of Effectiveness, in each case modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities included therein. For the avoidance of doubt, all Shares and Commitment Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued to the Investor or its designee only as DWAC Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other than those referred to in this Section 9.1(iv) will be given by the Company to the Transfer Agent, or any successor transfer agent of the Company, with respect to the Shares and the Commitment Shares from and after Commencement, and the Shares and the Commitment Shares (as applicable) covered by the Initial Prospectus Supplement or any post-effective amendment thereof, or any New Registration Statement or post-effective amendment thereof, as applicable, shall otherwise be freely transferable on the books and records of the Company and no stop transfer instructions shall be maintained against the transfer thereof. The Company agrees that if the Company fails to fully comply with the provisions of this Section 9.1(iv) within three (3) Trading Days after the date on which the Investor has provided the deliverables referred to above that the Investor is required to provide to the Company or the Transfer Agent, the Company shall, at the Investor’s written instruction, purchase from the Investor all shares of Common Stock purchased or acquired by the Investor pursuant to this Agreement that contain the restrictive legend referred to in Section 9.1(iii) hereof (or any similar restrictive legend) at the greater of (i) the purchase price paid for such shares of Common Stock (as applicable) and (ii) the Closing Sale Price of the Common Stock on the date of the Investor’s written instruction.

 

44

 

 

Section 9.2.           Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial.

 

(i)            The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Company, on the one hand, and the Investor, on the other hand, shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

(ii)            Each of the Company and the Investor (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of the United States sitting in the State of New York for the purposes of any suit, action or proceeding arising out of or relating to this Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 9.2 shall affect or limit any right to serve process in any other manner permitted by law.

 

(iii)          EACH OF THE COMPANY AND THE INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.2.

 

45

 

 

Section 9.3.           Entire Agreement. The Transaction Documents set forth the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written, with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth in the Transaction Documents. The Disclosure Schedule and all exhibits to this Agreement are hereby incorporated by reference in, and made a part of, this Agreement as if set forth in full herein.

 

Section 9.4.           Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery or electronic mail delivery at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The address for such communications shall be:

 

If to the Company:

 

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Attention: Maria Maccecchini, Ph.D

Email: maccecchini@annovisbio.com

 

With a copy (which shall not constitute notice) to:

 

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attention: Mitchell S. Nussbaum, Esq.

 

If to the Investor:

 

Keystone Capital Partners, LLC

139 Fulton Street, Suite 412

New York, NY 10038
Telephone Number: (646) 349-0916

Email: fz@keystone-cp.com

Attention: Fredric G. Zaino

 

With a copy (which shall not constitute notice) to:

 

Pryor Cashman LLP

7 Times Square

New York, NY 10036

Attention: M. Ali Panjwani, Esq.

 

46

 

 

Either party hereto may from time to time change its address for notices by giving at least five (5) days’ advance written notice of such changed address to the other party hereto.

 

Section 9.5.           Waivers. No provision of this Agreement may be waived by the parties from and after the date that is one (1) Trading Day immediately preceding the filing of the Initial Prospectus Supplement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercises thereof or of any other right, power or privilege.

 

Section 9.6.           Amendments. No provision of this Agreement may be amended by the parties from and after the date that is one (1) Trading Day immediately preceding the filing of the Initial Prospectus Supplement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.

 

Section 9.7.           Headings. The article, section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

Section 9.8.           Construction. The parties agree that each of them and their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents. In addition, each and every reference to share prices and number of shares of Common Stock in any Transaction Document shall, in all cases, be subject to adjustment for any stock splits, stock combinations, stock dividends, recapitalizations, reorganizations and other similar transactions that occur on or after the date of this Agreement. Any reference in this Agreement to “Dollars” or “$” shall mean the lawful currency of the United States of America. Any references to “Section” or “Article” in this Agreement shall, unless otherwise expressly stated herein, refer to the applicable Section or Article of this Agreement.

 

Section 9.9.           Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors. Neither the Company nor the Investor may assign this Agreement or any of their respective rights or obligations hereunder to any Person.

 

Section 9.10.         No Third Party Beneficiaries. This Agreement is intended only for the benefit of the parties hereto and their respective successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

47

 

 

Section 9.11.         Governing Law. This Agreement shall be governed by and construed in accordance with the internal procedural and substantive laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of the laws of any other jurisdiction.

 

Section 9.12.         Survival. The representations, warranties, covenants and agreements of the Company and the Investor contained in this Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided, however, that (i) the provisions of Article VII (Termination) and Article VIII (Indemnification) shall remain in full force and effect indefinitely notwithstanding such termination.

 

Section 9.13.         Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

Section 9.14.         Publicity. The Company shall afford the Investor and its counsel with a reasonable opportunity to review and comment upon, shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release, Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, prior to the issuance, filing or public disclosure thereof. For the avoidance of doubt, the Company shall not be required to submit for review any such disclosure (i) contained in periodic reports filed with the Commission under the Exchange Act if it shall have previously provided the same disclosure to the Investor or its counsel for review in connection with a previous filing or (ii) any Prospectus Supplement if it contains disclosure that does not reference the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby.

 

Section 9.15.         Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent possible.

 

Section 9.16.         Further Assurances. From and after the Closing Date, upon the request of the Investor or the Company, each of the Company and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

[Signature Pages Follow]

 

48

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officer as of the date first above written.

 

  THE COMPANY:
   
  ANNOVIS BIO, INC.:
   
   
  By:           
  Name:
  Title:
   
   
  THE INVESTOR:
   
  KEYSTONE CAPITAL PARTNERS, LLC:
   
   
  By:  
  Name:
  Title:

 

49

 

 

ANNEX I TO THE
COMMON STOCK PURCHASE AGREEMENT
DEFINITIONS

 

Additional VWAP Purchase” shall have the meaning assigned to such term in Section 2.3.

 

Additional VWAP Purchase Commencement Time” means, the latest of (A) the applicable VWAP Purchase Termination Time with respect to the corresponding VWAP Purchase on such Additional VWAP Purchase Date, (B) the applicable Additional VWAP Purchase Termination Time with respect to the most recently completed prior Additional VWAP Purchase on such Additional VWAP Purchase Date, as applicable, and (C) the time at which all shares of Common Stock subject to all prior VWAP Purchases and Additional VWAP Purchases (as applicable), including, without limitation, those that have been effected on the same business day as the applicable Additional VWAP Purchase.

 

Additional VWAP Purchase Confirmation” shall have the meaning assigned to such term in Section 2.3 and shall be in the form attached hereto as Annex 2.3C.

 

Additional VWAP Purchase Date” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the Trading Day (i) that is also the VWAP Purchase Date for the corresponding VWAP Purchase referred to in clause (i) of the second sentence of Section 2.3 and (ii) on which the Investor receives, prior to 2:00 p.m., New York City time, on such Trading Day, a valid Additional VWAP Purchase Notice for such Additional VWAP Purchase in accordance with this Agreement.

 

Additional VWAP Purchase Maximum Amount” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice for the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section 2.3 and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase.

 

Additional VWAP Purchase Notice” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, an irrevocable written notice delivered by the Company to the Investor, prior to 2:00 p.m., New York City time, on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase, directing the Investor to purchase an Additional VWAP Purchase Share Amount (such specified Additional VWAP Purchase Share Amount subject to adjustment as set forth in Section 2.3 as necessary to give effect to the Additional VWAP Purchase Maximum Amount), at the applicable Additional VWAP Purchase Price therefor on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase in accordance with this Agreement.

 

 I-1 

 

 

Additional VWAP Purchase Period” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase beginning at the applicable Additional VWAP Purchase Commencement Time and ending at the applicable Additional VWAP Purchase Termination Time.

 

Additional VWAP Purchase Price” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the purchase price per Share to be purchased by the Investor in such Additional VWAP Purchase equal to ninety-five percent (95%) of the lower of (i) the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase, and (ii) the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).

 

Additional VWAP Purchase Share Amount” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the number of Shares to be purchased by the Investor in such Additional VWAP Purchase as specified by the Company in the applicable Additional VWAP Purchase Notice, which number of Shares shall not exceed the applicable Additional VWAP Purchase Maximum Amount.

 

Additional VWAP Purchase Share Percentage” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, thirty percent (30%).

 

Additional VWAP Purchase Share Volume Maximum” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, a number of shares of Common Stock equal to (i) the number of Shares specified by the Company in the applicable Additional VWAP Purchase Notice as the Additional VWAP Purchase Share Amount to be purchased by the Investor in such Additional VWAP Purchase, divided by (ii) the Additional VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).

 

Additional VWAP Purchase Termination Time” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the earliest of (i) 4:00 p.m., New York City time, on the applicable Additional VWAP Purchase Date, or such other time publicly announced by the Trading Market as the official close of trading on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, by such Eligible Market as the official close of trading on such Eligible Market) on such applicable Additional VWAP Purchase Date, (ii) such time, from and after the Additional VWAP Purchase Commencement Time for such Additional VWAP Purchase, that the trading volume of shares of Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) has exceeded the applicable Additional VWAP Purchase Share Volume Maximum and (iii) such time, from and after the Additional VWAP Purchase Commencement Time for such Additional VWAP Purchase, that any sale price of the Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) has fallen below the applicable Floor Price for such applicable Additional VWAP Purchase.

 

 I-2 

 

 

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with a Person, as such terms are used in and construed under Rule 144.

 

Aggregate Limit” shall have the meaning assigned to such term in Section 2.4(a).

 

Agreement” shall have the meaning assigned to such term in the preamble of this Agreement.

 

Applicable Laws” shall have the meaning assigned to such term in Section 4.13.

 

Bankruptcy Law” means Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.

 

Beneficial Ownership Limitation” shall have the meaning assigned to such term in Section 2.5.

 

Bloomberg” means Bloomberg, L.P.

 

Bring Down Opinion” shall have the meaning assigned to such term in Section 5.15.

 

Broker-Dealer” shall have the meaning assigned to such term in Section 5.13.

 

Bylaws” shall have the meaning assigned to such term in Section 4.4.

 

Charter” shall have the meaning assigned to such term in Section 3.3.

 

Closing” shall have the meaning assigned to such term in Section 1.2

 

Closing Date” means the date of this Agreement.

 

Closing Sale Price” means, for the Common Stock as of any date, the last closing trade price for the Common Stock on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market), as reported by Bloomberg, or, if the Trading Market (or such Eligible Market, as applicable) begins to operate on an extended hours basis and does not designate the closing trade price for the Common Stock, then the last trade price for the Common Stock prior to 4:00 p.m., New York City time, as reported by Bloomberg. All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period.

 

Code” means the Internal Revenue Code of 1986, as amended.

 

Commencement” shall have the meaning assigned to such term in Section 2.1

 

Commencement Date” shall have the meaning assigned to such term in Section 2.1.

 

Commencement Irrevocable Transfer Agent Instructions” shall have the meaning assigned to such term in Section 9.1(iv).

 

 I-3 

 

 

Commission” means the U.S. Securities and Exchange Commission or any successor entity.

 

Commission Documents” shall mean (1) all reports, schedules, registrations, forms, statements, information and other documents filed with or furnished to the Commission by the Company pursuant to the reporting requirements of the Exchange Act, including all material filed with or furnished to the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act since December 31, 2022, and which hereafter shall be filed with or furnished to the Commission by the Company, including, without limitation, the Current Report, (2) each Registration Statement, as the same may be amended from time to time, the Prospectus contained therein and each Prospectus Supplement thereto and (3) all information contained in such filings and all documents and disclosures that have been and heretofore shall be incorporated by reference therein.

 

Commitment Shares” means (i) 10,181 worth of the Company’s Common Stock issuable upon execution of this Agreement, valued at the VWAP Purchase Price as of such date (the “Initial Commitment Shares”), (ii)  worth of the Company’s Common Stock issuable on the ninetieth (90) calendar day following the Closing Date, valued at the VWAP Purchase Price as of such date (the “First Back End Commitment Shares”) and (iii) $150,000 worth of the Company’s Common Stock issuable on the one hundred and eightieth (180) calendar day following the Closing Date, valued at the VWAP Purchase Price as of such date (the “Second Back End Commitment Shares,” and together with the First Back End Commitment Shares, the “Back End Commitment Shares”).

 

Common Stock” shall have the meaning assigned to such term in the recitals of this Agreement.

 

Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

Company” shall have the meaning assigned to such term in the preamble of this Agreement.

 

Compliance Certificate” shall have the meaning assigned to such term in Section 6.2(ii).

 

Current Report” shall have the meaning assigned to such term in Section 1.3.

 

Custodian” shall mean any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

Damages” shall have the meaning assigned to such term in Section 8.1.

 

Dilutive Issuance” shall have the meaning assigned to such term in Section 5.6(ii).

 

Disclosure Schedule” shall have the meaning assigned to such term in Section 4.1.

 

 I-4 

 

 

Disqualification Event” shall have the meaning assigned to such term in Section 4.37.

 

DTC” means The Depository Trust Company, a subsidiary of The Depository Trust & Clearing Corporation, or any successor thereto.

 

DWAC” shall have the meaning assigned to such term in Section 2.6.

 

DWAC Shares” means shares of Common Stock issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on resale and without stop transfer instructions maintained against the transfer thereof and (iii) timely credited by the Company to the Investor’s or its designated Broker-Dealer at which the account or accounts to be credited with the Securities being purchased by Investor are maintained specified DWAC account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

EDGAR” means the Commission’s Electronic Data Gathering, Analysis and Retrieval System.

 

Effective Date” means, with respect to the Initial Prospectus Supplement filed pursuant to Section 2(a) of the Registration Rights Agreement (or any post-effective amendment thereto) or any New Registration Statement filed pursuant to Section 2(c) of the Registration Rights Agreement (or any post-effective amendment thereto), as applicable, the date on which the Initial Prospectus Supplement (or any post-effective amendment thereto) or any New Registration Statement (or any post-effective amendment thereto) is declared effective by the Commission.

 

Effectiveness Deadline” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

Eligible Market” means The New York Stock Exchange (“NYSE”), The New York Stock Exchange American, Nasdaq Capital Market, The Nasdaq Global Market, or The Nasdaq Global Select Market (or any nationally recognized successor to any of the foregoing).

 

Environmental Laws” shall have the meaning assigned to such term in Section 4.16 hereof.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

 I-5 

 

 

Exempt Issuance” means the issuance of (a) Common Stock, options or other equity incentive awards to employees, officers, directors or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the Company’s Board of Directors or a majority of the members of a committee of the Board of Directors established for such purpose, (b) (1) any Securities issued to the Investor pursuant to this Agreement, (2) any securities issued upon the exercise or exchange of or conversion of any shares of Common Stock or Common Stock Equivalents held by the Investor at any time, or (3) any securities issued upon the exercise or exchange of or conversion of any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities referred to in this clause (3) have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions approved by the Company’s Board of Directors or a majority of the members of a committee of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions can have a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, or (d) Common Stock issued by the Company by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, exclusively through a registered broker-dealer, as the Company’s sales agent, pursuant to one or more written agreements between the Company and such registered broker-dealer.

 

FCPA” shall have the meaning assigned to such term in Section 4.33.

 

Filed Commission Document” shall have the meaning assigned to such term in Section 4.6.

 

Filing Deadline” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

FINRA” means the Financial Industry Regulatory Authority.

 

Fixed Purchase” shall have the meaning assigned to such term in Section 2.1.

 

Fixed Purchase Date” means, with respect to a Fixed Purchase made pursuant to Section 2.1, the Trading Day on which the Investor receives, after 4:00 p.m., New York City time, but prior to 5:30 p.m., New York City time, on such Trading Day, a valid Fixed Purchase Notice for such Fixed Purchase in accordance with this Agreement.

 

Fixed Purchase Maximum Amount” means, with respect to a Fixed Purchase made pursuant to Section 2.1, the lesser of 25,000 shares of Common Stock or $250,000.

 

Fixed Purchase Notice” means, with respect to a Fixed Purchase pursuant to Section 2.1, an irrevocable written notice delivered by the Company to the Investor directing the Investor to purchase a Fixed Purchase Share Amount (such specified Fixed Purchase Share Amount subject to adjustment as set forth in Section 2.1 as necessary to give effect to the Fixed Purchase Maximum Amount), at the applicable Fixed Purchase Price therefor on the applicable Fixed Purchase Date for such Fixed Purchase in accordance with this Agreement.

 

Fixed Purchase Price” means, with respect to a Fixed Purchase made pursuant to Section 2.1, the purchase price per Share to be purchased by the Investor in such Fixed Purchase equal to the lesser of 95% (i) of the daily volume weighted average price of the Company’s Common Stock on the NYSE, as reported by Bloomberg Financial LP using the AQR function for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase and (ii) of the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date for such Fixed Purchase during the full Trading Day on the NYSE on such applicable Purchase Date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of this Agreement).

 

 I-6 

 

 

Fixed Purchase Share Amount” means, with respect to a Fixed Purchase made pursuant to Section 2.1, the number of Shares to be purchased by the Investor in such Fixed Purchase as specified by the Company in the applicable Fixed Purchase Notice, which number of Shares shall not exceed the applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date).

 

Floor Price” means a price equal to 85% of the Closing Price on the Trading Day the applicable Additional VWAP Purchase Notice or VWAP Purchase Notice is delivered to Investor along with the Fixed Purchase Notice.

 

Fundamental Transaction” means that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, with the result that the holders of the Company’s capital stock immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding voting power of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender or exchange offer by another Person that is accepted by the holders of the Company’s Voting Stock representing more than 50% of the total voting power of the Company’s Voting Stock (excluding any Voting Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires Voting Stock of the Company representing more than 50% of the total voting power of the Company’s Voting Stock (not including any Voting Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of Voting Stock of the Company representing more than 50% of the total voting power of the Company’s Voting Stock.

 

GAAP” shall have the meaning assigned to such term in Section 4.6(b).

 

Initial Prospectus Supplement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

Investment Period” means the period commencing on the Effective Date of the Initial Prospectus Supplement and expiring on the date this Agreement is terminated pursuant to Article VII.

 

 I-7 

 

 

Investor” shall have the meaning assigned to such term in the preamble of this Agreement.

 

Investor Expense Reimbursement” shall have the meaning assigned to such term in Section 9.1(i).

 

Investor Party” shall have the meaning assigned to such term in Section 8.1.

 

Issuer Covered Person” shall have the meaning assigned to such term in Section 4.37.

 

IT Systems” shall have the meaning assigned to such term in Section 4.36.

 

Knowledge” means, with respect to the Company, the actual knowledge of the Company’s Chief Executive Officer Chief Medical Officer, and President, its Chief Financial Officer and Treasurer, in each case after reasonable inquiry of all officers, directors and employees of the Company under their direct supervision who would reasonably be expected to have knowledge or information with respect to the matter in question.

 

Material Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company other than any material adverse effect that resulted primarily from (A) any change in the United States or foreign economies or securities or financial markets in general, (B) any change that generally affects the industry in which the Company operates, (C) any change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor, its Affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement and the Registration Rights Agreement, (E) the effect of any change in applicable laws or accounting rules, or (F) any change resulting from compliance with terms of this Agreement or the Registration Rights Agreement or the consummation of the transactions contemplated by this Agreement and the Registration Rights Agreement, or (iii) the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document to which it is a party to be performed as of the date of determination.

 

Material Agreements” shall have the meaning assigned to such term in Section 4.17.

 

Money Laundering Laws” shall have the meaning assigned to such term in Section 4.34.

 

New Registration Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

Notice Delivery Time” shall have the meaning assigned to such term in Section 6.3.

 

Notice of Effectiveness” shall have the meaning assigned to such term in Section 9.1(iv).

 

OFAC” shall have the meaning assigned to such term in Section 4.35.

 

 I-8 

 

 

Person” means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

Personal Data” shall have the meaning assigned to such term in Section 4.36.

 

Prospectus” means the prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement, including the documents incorporated by reference therein.

 

Prospectus Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under the Securities Act, including the documents incorporated by reference therein.

 

Reference Period” shall have the meaning assigned to such term in Section 5.6(ii).

 

Reference Price” shall have the meaning assigned to such term in Section 5.6(ii).

 

Registrable Securities” shall have the meaning assigned to such term in the Registration Rights Agreement, and shall include the Commitment Shares.

 

Registration Rights Agreement” shall have the meaning assigned to such term in the recitals hereof.

 

Regulation D” shall have the meaning assigned to such term in the recitals of this Agreement.

 

Restricted Period” shall have the meaning assigned to such term in Section 5.9(i).

 

Restricted Person” shall have the meaning assigned to such term in Section 5.9(i).

 

Restricted Persons” shall have the meaning assigned to such term in Section 5.9(i).

 

Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect.

 

Sale Price” means any trade price for a share of Common Stock executed on the Trading Market (or if the Common Stock is then traded on an Eligible Market, on such Eligible Market) between 9:30 a.m., New York City time, or such other time publicly announced by the Trading Market or such other Eligible Market, as the case may be, and ending at 4:00 p.m., New York City time, on the applicable Purchase Date, as reported by Bloomberg.

 

Sanctioned Countries” shall have the meaning assigned to such term in Section 4.35.

 

Sanctioned Country” shall have the meaning assigned to such term in Section 4.35.

 

Sanctioned Persons” shall have the meaning assigned to such term in Section 4.35.

 

 I-9 

 

 

Sanctions” shall have the meaning assigned to such term in Section 4.35.

 

Section 4(a)(2)” shall have the meaning assigned to such term in the recitals of this Agreement.

 

Securitiesmeans, collectively, the Shares and the Commitment Shares.

 

Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.

 

Shares” shall mean the shares of Common Stock that are and/or may be purchased by the Investor under this Agreement pursuant to one or more Fixed Purchase Notices, VWAP Purchase Notices or Additional VWAP Purchase Notices, but not including the Commitment Shares.

 

Short Sales” shall mean “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act.

 

Stock Plan” shall have the meaning assigned to such term in Section 4.22.

 

Total Purchase Commitment” shall have the meaning assigned to such term in Section 1.1.

 

Trading Day” shall mean any day on which the Trading Market or, if the Common Stock is then listed on an Eligible Market, such Eligible Market is open for trading, including any day on which the Trading Market (or such Eligible Market, as applicable) is open for trading for a period of time less than the customary time.

 

Trading Market” means the New York Stock Exchange (or any nationally recognized successor thereto).

 

Transaction Documents” means, collectively, this Agreement (as qualified by the Commission Documents and the Disclosure Schedule) and the exhibits hereto, the Registration Rights Agreement and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby.

 

Transfer Agent” means Equiniti Trust Company LLC, or such other Person who is then serving as the transfer agent for the Company in respect of the Common Stock.

 

 I-10 

 

 

Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any equity or debt securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents either (A) at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such equity or debt securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such equity or debt security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (including, without limitation, any “full ratchet” or “weighted average” anti-dilution provisions, but not including any standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction), (ii) issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock Equivalents, either (A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction), or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or other similar provision or mechanism (including, without limitation, a “Black-Scholes” put or call right, other than in connection with a “fundamental transaction”) that provides for the issuance of additional equity securities of the Company or the payment of cash by the Company, or (iii) enters into any agreement with any Person other than the Investor or an Affiliate of the Investor, including, but not limited to, an “equity line of credit” or “at the market offering” or other continuous offering or similar offering of Common Stock or Common Stock Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at a future determined price.

 

Voting Stock” means securities of any class or kind having the power to vote generally for the election of directors, managers or other voting members of the governing body of the Company or any successor thereto.

 

VWAP” means, for the Common Stock for a specified period, the dollar volume-weighted average price for the Common Stock on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market), for such period, as reported by Bloomberg through its “AQR” function. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during such period.

 

VWAP Purchase” shall have the meaning assigned to such term in Section 2.2.

 

VWAP Purchase Commencement Time” means, with respect to a VWAP Purchase made pursuant to Section 2.2, 9:30 a.m., New York City time, on the applicable VWAP Purchase Date, or such other time publicly announced by the Trading Market (or, if the Common Stock is then listed on an Eligible Market, by such Eligible Market) as the official open (or commencement) of trading on the Trading Market (or such Eligible Market, as applicable) on such applicable VWAP Purchase Date.

 

VWAP Purchase Confirmation” shall have the meaning assigned to such term in Section 2.2 and shall be in the form attached hereto as Annex 2.2B.

 

VWAP Purchase Date” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the Trading Day immediately following the applicable Fixed Purchase Date with respect to the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section 3.2, on which the Investor receives, concurrently with the receipt of the applicable Fixed Purchase Notice for such corresponding Fixed Purchase, after 4:00 p.m., New York City time, but prior to 5:30 p.m., New York City time, on such applicable Fixed Purchase Date, a valid VWAP Purchase Notice for such VWAP Purchase in accordance with this Agreement.

 

 I-11 

 

 

VWAP Purchase Maximum Amount” means, with respect to a VWAP Purchase made pursuant to Section 3.2, a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice for the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section 2.2 and (ii) 30% of the trading volume in the Company’s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date.

 

VWAP Purchase Notice” means, with respect to a VWAP Purchase made pursuant to Section 2.2, an irrevocable written notice delivered by the Company to the Investor (concurrently with the delivery of the applicable Fixed Purchase Notice by the Company to the Investor on the applicable Fixed Purchase Date with respect to the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section 2.2) directing the Investor to purchase a VWAP Purchase Share Amount (such specified VWAP Purchase Share Amount subject to adjustment as set forth in Section 3.2 as necessary to give effect to the VWAP Purchase Maximum Amount), at the applicable VWAP Purchase Price therefor on the applicable VWAP Purchase Date for such VWAP Purchase in accordance with this Agreement.

 

VWAP Purchase Period” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the period on the applicable VWAP Purchase Date for such VWAP Purchase beginning at the applicable VWAP Purchase Commencement Time and ending at the applicable VWAP Purchase Termination Time.

 

VWAP Purchase Price” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the purchase price per Share to be purchased by the Investor in such VWAP Purchase equal to the lesser of ninety-five percent (95%) of (i) the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date and (ii) the VWAP during the applicable VWAP Purchase Period.

 

VWAP Purchase Share Amount” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the number of Shares to be purchased by the Investor in such VWAP Purchase as specified by the Company in the applicable VWAP Purchase Notice, which number of Shares shall not exceed the applicable VWAP Purchase Maximum Amount.

 

VWAP Purchase Share Percentage” means, with respect to a VWAP Purchase made pursuant to Section 2.2, thirty percent (30%).

 

VWAP Purchase Share Volume Maximum” means, with respect to a VWAP Purchase made pursuant to Section 2.2, a number of shares of Common Stock equal to (i) the number of Shares specified by the Company in the applicable VWAP Purchase Notice as the VWAP Purchase Share Amount to be purchased by the Investor in such VWAP Purchase, divided by (ii) the VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).

 

 I-12 

 

 

VWAP Purchase Termination Time” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the earliest of (i) 2:00 p.m., New York City time, on the applicable VWAP Purchase Date, or such other time publicly announced by the Trading Market (or, if the Common Stock is then listed on an Eligible Market, by such Eligible Market) as the official close of trading on the Trading Market on such applicable VWAP Purchase Date, (ii) such time, from and after the VWAP Purchase Commencement Time for such VWAP Purchase, that the trading volume of shares of Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) has exceeded the applicable VWAP Purchase Share Volume Maximum and (iii) such time, from and after the VWAP Purchase Commencement Time for such VWAP Purchase, that any sale price of the Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) has fallen below the applicable Floor Price for such applicable VWAP Purchase.

 

 I-13 

 

 

EXHIBIT A TO THE
COMMON STOCK PURCHASE AGREEMENT

 

REGISTRATION RIGHTS AGREEMENT

 

[TO BE FURNISHED SEPARATELY]

 

 A-1 

 

 

EXHIBIT B TO THE
COMMON STOCK PURCHASE AGREEMENT
CERTiFICATE OF THE COMPANY

 

CLOSING CERTIFICATE

 

__, 2024

 

The undersigned, the [●] of Annovis Bio, Inc., a Delaware corporation (the “Company”), delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of April 25, 2024 (the “Agreement”), by and between the Company and Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and hereby certifies on the date hereof that (capitalized terms used herein without definition have the meanings assigned to them in the Agreement):

 

1.            Attached hereto as Exhibit A is a true, complete and correct copy of the Certificate of Incorporation of the Company, as amended through the date hereof, as filed with the State of Delaware. The Certificate of Incorporation of the Company has not been further amended or restated, and no document with respect to any amendment to the Certificate of Incorporation of the Company has been filed in the State of Delaware since the date shown on the face of the state certification relating to the Company’s Certificate of Incorporation, which is in full force and effect on the date hereof, and no action has been taken by the Company in contemplation of any such amendment or the dissolution, merger or consolidation of the Company.

 

2.            Attached hereto as Exhibit B is a true and complete copy of the Bylaws of the Company, as amended and restated through, and as in full force and effect on, the date hereof, and no proposal for any amendment, repeal or other modification to the Bylaws of the Company has been taken or is currently pending before the Board of Directors or stockholders of the Company.

 

3.            The Board of Directors of the Company has approved the transactions contemplated by the Transaction Documents; said approval has not been amended, rescinded or modified and remains in full force and effect as of the date hereof. Attached hereto as Exhibit C are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company via unanimous written consent on [●], 2024.

 

4.            Each person who, as an officer of the Company, or as attorney-in-fact of an officer of the Company, signed the Transaction Documents to which the Company is a party, was duly elected, qualified and acting as such officer or duly appointed and acting as such attorney-in-fact, and the signature of each such person appearing on any such document is his genuine signature.

 

IN WITNESS WHEREOF, I have signed my name as of the date first above written.

 

   
  Name:
  Title:

 

 B-1 

 

 

EXHIBIT C TO THE
COMMON STOCK PURCHASE AGREEMENT
COMPLIANCE CERTIFICATE

 

The undersigned, the [●] of Annovis Bio, Inc., a Delaware corporation (the “Company”), delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of April 25, 2024 (the “Agreement”), by and between the Company and Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and hereby certifies on the date hereof that, to the best of his knowledge after reasonable investigation, on behalf of the Company (capitalized terms used herein without definition have the meanings assigned to them in the Agreement):

 

1.            The undersigned is the duly appointed [●] of the Company.

 

2.            Except as set forth in the attached Disclosure Schedule, the representations and warranties of the Company set forth in Article IV of the Agreement (i) that are not qualified by “materiality” or “Material Adverse Effect” are true and correct in all material respects as of [the Commencement Date] [the date hereof] with the same force and effect as if made on [the Commencement Date] [the date hereof], except to the extent such representations and warranties are as of another date, in which case, such representations and warranties are true and correct in all material respects as of such other date and (ii) that are qualified by “materiality” or “Material Adverse Effect” are true and correct as of [the Commencement Date] [the date hereof] with the same force and effect as if made on [the Commencement Date] [the date hereof], except to the extent such representations and warranties are as of another date, in which case, such representations and warranties are true and correct as of such other date.

 

3.            The Company has performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by the Company, respectively, [at or prior to Commencement][on or prior to the date hereof].

 

4.            The Shares issuable in respect of each Fixed Purchase Notice, each VWAP Purchase Notice, and each Additional VWAP Purchase Notice effected pursuant to the Agreement shall be delivered to the Investor electronically as DWAC Shares, and shall be freely tradable and transferable and without restriction on resale and without any stop transfer instructions maintained against such Shares.

 

5.            As of [the Commencement Date][the date hereof], the Company does not possess any material non-public information.

 

6.            As of [the Commencement Date][the date hereof], the Company has reserved out of its authorized and unissued Common Stock, [●] shares of Common Stock solely for the purpose of effecting Fixed Purchases, VWAP Purchases and Additional VWAP Purchases under the Agreement.

 

7.            No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus under the Securities Act has been issued and no proceedings for such purpose or pursuant to Section 8A of the Securities Act are pending before or, to the Knowledge of the Company, threatened by the Commission.

 

The undersigned has executed this Certificate this [●] day of [●], 2024.

 

  By:  
     
  Name:  
     
  Title:  

 

 C-1 

 

 

DISCLOSURE SCHEDULEs
RELATING TO THE COMMON STOCK
PURCHASE AGREEMENT, DATED AS OF APRIL 25, 2024
BY AND AMONG ANNOVIS BIO, INC. AND Keystone Capital Partners, LLC

 

This disclosure schedules are made and given pursuant to Article IV of the Common Stock Purchase Agreement, dated as of April 25, 2024 (the “Agreement”), by and between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”). Unless the context otherwise requires, all capitalized terms are used herein as defined in the Agreement. The numbers below correspond to the section numbers of representations and warranties in the Agreement most directly modified by the below exceptions.

 

 C-2 

 

 

ANNEX 2.1 TO THE

COMMON STOCK PURCHASE AGREEMENT FORM OF FIXED PURCHASE NOTICE

 

To:    
E-mail:    

 

Reference is made to the Common Stock Purchase Agreement dated as of April 25 2024, (the “Purchase Agreement”) between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.

 

In accordance with and pursuant to Section 2.1 of the Purchase Agreement, the Company hereby issues this Fixed Purchase Notice to exercise a Fixed Purchase for the Fixed Purchase Share Amount indicated below.

 

Fixed Purchase Share Amount (number of Shares):    
Fixed Purchase Exercise Date:    
Fixed Purchase Price (per Share):    
Total Aggregate Fixed Purchase Price:    
Fixed Purchase Share Delivery Date:    
Fixed Purchase Settlement Date:    
Dollar Amount of Common Stock
Currently Available under the Aggregate Limit:
      

 

 

Dated:      Annovis Bio, Inc.
     
      By:             
    Name:
    Title:
    Address: Email

 

AGREED AND ACCEPTED:  
KEYSTONE CAPITAL PARTNERS, LLC  
   
  By:    
  Name:  
  Title:  

 

 C-3 

 

 

ANNEX 2.2 TO THE

COMMON STOCK PURCHASE AGREEMENT FORM OF VWAP PURCHASE NOTICE

 

To:    
E-mail:    

 

Reference is made to the Common Stock Purchase Agreement dated as of April 25, 2024, (the “Purchase Agreement”) between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.

 

In accordance with and pursuant to Section 2.2 of the Purchase Agreement, the Company hereby issues this VWAP Purchase Notice to exercise a VWAP Purchase for the VWAP Purchase Share Amount indicated below.

 

VWAP Purchase Share Amount (number of Shares):    
VWAP Purchase Exercise Date:    
VWAP Purchase Date:    
VWAP Purchase Share Delivery Date:    
VWAP Purchase Settlement Date:    
Dollar Amount of Common Stock Currently
Available under the Aggregate Limit:
   

 

 

Dated:      Annovis Bio, Inc.
     
      By:             
    Name:
    Title:
    Address:
    Email:

 

AGREED AND ACCEPTED:  
KEYSTONE CAPITAL PARTNERS, LLC  
   
  By:    
  Name:  
  Title  

 

 C-4 

 

 

ANNEX 2.2B TO THE

COMMON STOCK PURCHASE AGREEMENT FORM OF VWAP PURCHASE CONFIRMATION

 

To:    
E-mail    

 

Reference is made to the Common Stock Purchase Agreement dated as of April 25, 2024, (the “Purchase Agreement”) between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.

 

In accordance with and pursuant to Section 2.2 of the Purchase Agreement, the Investor hereby issues this VWAP Purchase Confirmation for the VWAP Purchase Share Amount indicated below.

 

VWAP Purchase Share Amount (number of Shares):    
VWAP Purchase Exercise Date:    
VWAP Purchase Date:    
VWAP Purchase Commencement Time:    
VWAP Purchase Termination Time:    
VWAP during the VWAP Purchase Period:    
Closing Sale Price on the VWAP Purchase Date:      
VWAP Purchase Price (per Share) (95% of
lower of two line items immediately above):
   
Total Aggregate VWAP Purchase Price:    
VWAP Purchase Share Delivery Date:    
VWAP Purchase Settlement Date:    

 

Dated:      KEYSTONE CAPITAL PARTNERS, LLC
     
      By:             
    Name:
    Title:
    Address:
    Email:

 

AGREED AND ACCEPTED:  
Annovis Bio, Inc.  
    
  By:        
  Name:  
  Title:  

 

 C-5 

 

 

ANNEX 2.3 TO THE

COMMON STOCK PURCHASE AGREEMENT FORM OF ADDITIONAL VWAP PURCHASE NOTICE

 

To:    
E-mail:    

 

Reference is made to the Common Stock Purchase Agreement dated as of April 25, 2024 (the “Purchase Agreement”) between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.

 

In accordance with and pursuant to Section 2.3 of the Purchase Agreement, the Company hereby issues this Additional VWAP Purchase Notice to exercise an Additional VWAP Purchase for the Additional VWAP Purchase Share Amount indicated below.

 

Additional VWAP Purchase Share Amount (number of Shares):    
Additional VWAP Purchase Date (indicate whether this is for the first, second, third, etc. Additional VWAP exercised by the Company on such Additional VWAP Purchase Date):    
Additional VWAP Purchase Share Delivery Date:    
Additional VWAP Purchase Settlement Date:    
Dollar Amount of Common Stock Currently Available under the Aggregate Limit:    

 

Dated:      Annovis Bio, Inc.
     
      By:             
    Name:
    Title:
    Address: Email:

 

AGREED AND ACCEPTED:  
KEYSTONE CAPITAL PARTNERS, LLC  
   
  By:    
  Name:  
  Title  

 

 C-6 

 

 

ANNEX 2.3B TO THE

COMMON STOCK PURCHASE AGREEMENT

FORM OF ADDITIONAL VWAP PURCHASE CONFIRMATION

 

To:    
E-mail    

 

Reference is made to the Common Stock Purchase Agreement dated as of April 25, 2024, (the “Purchase Agreement”) between Annovis Bio, Inc., a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.

 

In accordance with and pursuant to Section 2.3 of the Purchase Agreement, the Investor hereby issues this Additional VWAP Purchase Confirmation for the Additional VWAP Purchase Share Amount indicated below.

 

Additional VWAP Purchase Share Amount (number of Shares):    
Additional VWAP Purchase Date (indicate whether this is for the first, second, third, etc. Additional VWAP exercised by the Company on such Additional VWAP Purchase Date):    
Additional VWAP Purchase Commencement Time:    
Additional VWAP Purchase Termination Time:    
VWAP during the Additional VWAP Purchase Period:    
Closing Sale Price on the Additional VWAP Purchase Date:    
Additional VWAP Purchase Price (per Share)
(95% of lower of two line items immediately above):
   
Total Aggregate Additional VWAP Purchase Price:    
Additional VWAP Purchase Share Delivery Date:    
Additional VWAP Purchase Settlement Date:    

 

Dated:      KEYSTONE CAPITAL PARTNERS, LLC
     
      By:             
    Name:
    Title:
    Address:
    Email:

 

AGREED AND ACCEPTED:  
Annovis Bio, Inc.  
    
By:        
  Name:  
  Title:  

 

 C-7 

 

 

EX-10.2 3 tm2412796d1_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

 

REGISTRATION RIGHTS AGREEMENT

 

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 25, 2024, is by and between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and Annovis Bio, Inc., a Delaware corporation (the “Company”).

 

RECITALS

 

A.            The Company and the Investor have entered into that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Company may issue to the Investor, from time to time, up to 19.99% of the Company’s outstanding shares of Common Stock as of the date of this Agreement, par value $0.0001 per share (“Common Stock”), unless (i) stockholder approval is obtained to issue more than such 19.99% or (ii) the price of applicable sales of Common Stock to the Investor under this Agreement equals or exceeds the lower of (A) the official Closing Sale Price on the NYSE immediately preceding the delivery of the applicable Fixed Purchase notice, VWAP Purchase notice, or Additional VWAP Purchase notice to the Investor and (B) the average of the Closing Sale Prices of the Common Stock on the NYSE for the five business days immediately preceding the delivery of such Fixed Purchase notice, VWAP Purchase notice or Additional VWAP Purchase Notice, as applicable (in each case plus an incremental amount to take into account the Commitment Shares), such that the sales of such Common Stock to the Investor would not count toward the 19.99% because they are “at market” under applicable NYSE rules, as provided for in the Purchase Agreement.

 

B.            Pursuant to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, the Company shall cause to be issued to the Investor the Commitment Shares in accordance with the terms of the Purchase Agreement.

 

C.            Pursuant to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, and to induce the Investor to execute and deliver the Purchase Agreement, the Company has agreed to provide the Investor with certain registration rights with respect to the Registrable Securities (as defined herein) as set forth herein.

 

 

 

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein and in the Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound hereby, the Company and the Investor hereby agree as follows:

 

1.Definitions.

 

Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

(a)            Agreement” shall have the meaning assigned to such term in the preamble of this Agreement

 

(b)            Allowable Grace Period” shall have the meaning assigned to such term in Section 3(n).

 

(c)            Blue Sky Filing” shall have the meaning assigned to such term in Section 6(a).

 

(d)            Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in New York, New York are authorized or required by law to remain closed.

 

(e)            Claims” shall have the meaning assigned to such term in Section 6(a).

 

(f)            Commission” means the U.S. Securities and Exchange Commission or any successor entity.

 

(g)            Common Stock” shall have the meaning assigned to such term in the recitals to this Agreement.

 

(h)            Company” shall have the meaning assigned to such term in the preamble of this Agreement.

 

(i)            Effective Date” means the date that the applicable Registration Statement has been declared effective by the Commission.

 

(j)            Effectiveness Deadline” means with respect to any New Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the earlier of (A) the thirtieth (30th) calendar day following the date on which the Company was required to file such additional Registration Statement, if such Registration Statement is subject to review by the Commission, and (B) the 3rd (3rd) Business Day following the date the Company is notified (orally or in writing, whichever is earlier) by the Commission that such New Registration Statement will not be reviewed.

 

(k)            Filing Deadline” means (i) with respect to the Initial Prospectus Supplement required to be filed to pursuant to Section 2(a), the second (2nd) Business Day after the date of this Agreement and (ii) with respect to any New Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the tenth (10th) Business Day following the sale of substantially all of the Registrable Securities included in the Initial Prospectus Supplement or the most recent prior New Registration Statement, as applicable, or such other date as permitted by the Commission.

 

(l)            Indemnified Damages” shall have the meaning assigned to such term in Section 6(a).

 

 2 

 

 

(m)            Initial Prospectus Supplement” shall have the meaning assigned to such term in Section 2(a).

 

(n)            Investor” shall have the meaning assigned to such term in the preamble of this Agreement.

 

(o)            Investor Party” and “Investor Parties” shall have the meaning assigned to such terms in Section 6(a).

 

(p)            Legal Counsel” shall have the meaning assigned to such term in Section 2(b).

 

(q)            New Registration Statement” shall have the meaning assigned to such term in Section 2(c).

 

(r)            Person” means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

(s)            Prospectus” means the prospectus in the form included in the Registration Statement, as supplemented from time to time by any Prospectus Supplement, including the documents incorporated by reference therein.

 

(t)            Prospectus Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under the Securities Act, including the documents incorporated by reference therein.

 

(u)            Purchase Agreement” shall have the meaning assigned to such term in the recitals to this Agreement.

 

(v)            register,” “registered,” and “registration” refer to a registration effected by preparing and filing one or more Registration Statements in compliance with the Securities Act and pursuant to Rule 415 and the declaration of effectiveness of such Registration Statement(s) by the Commission.

 

(w)            Registrable Securities” means all of (i) the Shares, (ii) the Commitment Shares, as fully earned as of the date hereof and (iii) any capital stock of the Company issued or issuable with respect to such Shares or Commitment Shares, including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the Company into which the shares of Common Stock are converted or exchanged and shares of capital stock of a successor entity into which the shares of Common Stock are converted or exchanged, in each case until such time as such securities cease to be Registrable Securities pursuant to Section 2(f).

 

(x)            Registration Period” shall have the meaning assigned to such term in Section 3(a).

 

(y)            Registration Statement” means the Shelf Registration Statement and any other registration statement, including a New Registration Statement of the Company filed under the Securities Act that registers the Registrable Securities, as such registration statement or registration statements may be amended and supplemented from time to time, including all documents filed as part thereof or incorporated by reference therein.

 

 3 

 

 

(z)            Rule 144” means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar or successor rule or regulation of the Commission that may at any time permit the Investor to sell securities of the Company to the public without registration.

 

(aa)         Rule 415” means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar or successor rule or regulation of the Commission providing for offering securities on a delayed or continuous basis.

 

(bb)         Shelf Registration Statement” means the Company’s existing registration statement on Form S-3 (File No. 333-276814).

 

(cc)          Staff” shall have the meaning assigned to such term in Section 2(e).

 

(dd)         Violations” shall have the meaning assigned to such term in Section 6(a).

 

2.Registration.

 

(a)            Mandatory Registration. The Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the Commission a prospectus supplement to its Shelf Registration Statement covering (i) all of the Commitment Shares and (ii) the maximum number of additional Registrable Securities as shall be permitted to be included thereon in accordance with applicable Commission rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices) (the “Initial Prospectus Supplement”). Such Initial Prospectus Supplement shall contain the “Selling Stockholder” and “Plan of Distribution” sections in substantially the form attached hereto as Exhibit B.

 

(b)            Legal Counsel. Subject to Section 5 hereof, the Investor shall have the right to select one legal counsel to review and oversee, solely on its behalf, any registration pursuant to this Section 2 (“Legal Counsel”), which shall be Pryor Cashman LLP, or such other counsel as thereafter designated by the Investor. Except as provided under Section 9.1(i) of the Purchase Agreement, the Company shall have no obligation to reimburse the Investor for any and all legal fees and expenses of the Legal Counsel incurred in connection with the transactions contemplated hereby.

 

(c)            Sufficient Number of Shares Registered. If at any time all Registrable Securities are not covered by the Initial Prospectus Supplement filed pursuant to Section 2(a) as a result of Section 2(e) or otherwise, and if the Company desires to sell additional Shares to the Investor under the Agreement, the Company shall then use its best efforts to file with the Commission one or more additional Registration Statements so as to cover all of the Registrable Securities not covered by such Initial Prospectus Supplement, in each case, as soon as practicable (taking into account any position of the staff of the Commission (“Staff”) with respect to the date on which the Staff will permit such additional Registration Statement(s) to be filed with the Commission and the rules and regulations of the Commission) (each such additional Registration Statement, a “New Registration Statement”), but in no event later than the applicable Filing Deadline for such New Registration Statement(s). The Company shall use its commercially reasonable efforts to cause each such New Registration Statement to become effective as soon as practicable following the filing thereof with the Commission, but in no event later than the applicable Effectiveness Deadline for such New Registration Statement.

 

 4 

 

 

(d)            No Inclusion of Other Securities. In no event shall the Company include any securities other than Registrable Securities on any Registration Statement pursuant to Section 2(a) or Section 2(c) without consulting the Investor and Legal Counsel prior to filing such Registration Statement with the Commission.

 

(e)            Offering. If the Staff or the Commission seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), or if after the filing of any Registration Statement pursuant to Section 2(a) or Section 2(c), the Company is otherwise required by the Staff or the Commission to reduce the number of Registrable Securities included in such Registration Statement, then the Company shall reduce the number of Registrable Securities to be included in such Registration Statement (after consultation with the Investor and Legal Counsel as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the Commission shall so permit such Registration Statement to become effective and be used as aforesaid. Notwithstanding anything in this Agreement to the contrary, if after giving effect to the actions referred to in the immediately preceding sentence, the Staff or the Commission does not permit such Registration Statement to become effective and be used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), the Company shall not request acceleration of the Effective Date of such Registration Statement, the Company shall promptly (but in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant to Rule 477 under the Securities Act. In the event of any reduction in Registrable Securities pursuant to this paragraph, if the Company desires to sell any Shares to the Investor that are not covered by a Registration Statement or New Registration Statement, the Company shall then use its commercially reasonable efforts to file one or more New Registration Statements with the Commission in accordance with Section 2(c) until such time as all Registrable Securities have been included in Registration Statements that have been declared effective and the Prospectuses contained therein are available for use by the Investor.

 

(f)            Any Registrable Security shall cease to be a “Registrable Security” at the earliest of the following: (i) when a Registration Statement covering such Registrable Security becomes or has been declared effective by the Commission and such Registrable Security has been sold or disposed of pursuant to such effective Registration Statement; (ii) when such Registrable Security is held by the Company or one of its subsidiaries; and (iii) the date that is the later of (A) the first (1st) anniversary of the date of termination of the Purchase Agreement in accordance with Article VII of the Purchase Agreement and (B) the first (1st) anniversary of the date of the last sale of any Registrable Securities to the Investor pursuant to the Purchase Agreement.

 

 5 

 

 

3.Related Obligations.

 

The Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof, and, pursuant thereto, the Company shall have the following obligations:

 

(a)            The Company shall promptly prepare and file with the Commission the Initial Prospectus Supplement pursuant to Section 2(a) hereof and one or more New Registration Statements pursuant to Section 2(c) hereof with respect to the Registrable Securities, but in no event later than the applicable Filing Deadline therefor, and the Company use its commercially reasonable efforts to cause each such New Registration Statement to become effective as soon as practicable after such filing, but in no event later than the applicable Effectiveness Deadline therefor. Subject to Allowable Grace Periods, the Company shall keep each Registration Statement effective (and the Prospectus contained therein available for use) pursuant to Rule 415 for issuances and sales of the Registrable Securities by the Company to the Investor and for resales by the Investor on a continuous basis at then-prevailing market prices (and not fixed prices) at all times until the earlier of (i) the date on which the Investor shall have sold all of the Registrable Securities covered by such Registration Statement and (ii) the date of termination of the Purchase Agreement if as of such termination date the Investor holds no Registrable Securities (or, if applicable, the date on which such securities cease to be Registrable Securities after the date of termination of the Purchase Agreement) (the “Registration Period”). Notwithstanding anything to the contrary contained in this Agreement (but subject to the provisions of Section 3(o) hereof), the Company shall ensure that, when filed and at all times while effective, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the Prospectus (including, without limitation, all amendments and supplements thereto) used in connection with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of Prospectuses, in the light of the circumstances in which they were made) not misleading. The Company shall submit to the Commission, as soon as reasonably practicable after the date that the Company learns that no review of a particular Registration Statement will be made by the Staff or that the Staff has no further comments on a particular Registration Statement (as the case may be), a request for acceleration of effectiveness of such Registration Statement to a time and date as soon as reasonably practicable in accordance with Rule 461 under the Securities Act.

 

 6 

 

 

(b)            Subject to Section 3(c) of this Agreement, the Company shall use its commercially reasonable efforts to prepare and file with the Commission such amendments (including, without limitation, post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection with each such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep each such Registration Statement effective (and the Prospectus contained therein current and available for use) at all times during the Registration Period for such Registration Statement, and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company required to be covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the Investor. Without limiting the generality of the foregoing, the Company covenants and agrees that (i) at or before 5:30 p.m. (New York City time) on the second (2nd) Trading Day immediately following the Effective Date of the Initial Prospectus Supplement and any New Registration Statement (or any post-effective amendment thereto), the Company shall file with the Commission in accordance with Rule 424(b) under the Securities Act the Initial Prospectus Supplement to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment thereto), and (ii) if the transactions contemplated by any Fixed Purchase are material to the Company (individually or collectively with all other prior Fixed Purchases, VWAP Purchase, or Additional VWAP Purchase, as applicable, the consummation of which have not previously been reported in any Prospectus Supplement filed with the Commission under Rule 424(b) under the Securities Act or in any report, statement or other document filed by the Company with the Commission under the Exchange Act), or if otherwise required under the Securities Act (or the interpretations of the Commission thereof), in each case as reasonably determined by the Company and the Investor, then, within the time period prescribed under Rule 424(b) under the Securities Act, the Company shall file with the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act with respect to the applicable Fixed Purchase(s), VWAP Purchase(s) and Additional VWAP Purchase(s), as applicable, disclosing the total number of Shares that are to be (and, if applicable, have been) issued and sold to the Investor pursuant to such purchase(s), the total purchase price for the Shares subject to such purchase(s), the applicable purchases price(s) for such Shares and the net proceeds that are to be (and, if applicable, have been) received by the Company from the sale of such Shares. To the extent not previously disclosed in the Prospectus or a Prospectus Supplement, the Company shall disclose in its Quarterly Reports on Form 10-Q and in its Annual Reports on Form 10-K the information described in the immediately preceding sentence relating to all purchase(s) consummated during the relevant fiscal quarter and shall file such Quarterly Reports and Annual Reports with the Commission within the applicable time period prescribed for such report under the Exchange Act. In the case of amendments and supplements to any Registration Statement on Form S-1 or Prospectus related thereto which are required to be filed pursuant to this Agreement (including, without limitation, pursuant to this Section 3(b)) by reason of the Company filing a report on Form 8-K, Form 10-Q or Form 10-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement and Prospectus, if applicable, or shall file such amendments or supplements to the Registration Statement or Prospectus with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company to amend or supplement such Registration Statement or Prospectus, for the purpose of including or incorporating such report into such Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including, without limitation, any supplement thereto) included in each Registration Statement in accordance with the provisions of the Securities Act and with the securities or “Blue Sky” laws of the jurisdictions in which the Registrable Securities may be sold by the Investor, in connection with the resale of the Registrable Securities and for such period of time thereafter as such Prospectus (including, without limitation, any supplement thereto) (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be delivered in connection with resales of Registrable Securities.

 

 7 

 

 

(c)            The Company shall (A) permit Legal Counsel an opportunity to review and comment upon (i) each Registration Statement at least two (2) Business Days prior to its filing with the Commission and (ii) all amendments and supplements to each Registration Statement (including, without limitation, the Prospectus contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports or Prospectus Supplements the contents of which is limited to that set forth in such reports) within a reasonable number of days prior to their filing with the Commission, and (B) shall reasonably consider any comments of the Investor and Legal Counsel on any such Registration Statement or amendment or supplement thereto or to any Prospectus contained therein. The Company shall promptly furnish to Legal Counsel, without charge, (i) electronic copies of any correspondence from the Commission or the Staff to the Company or its representatives relating to each Registration Statement (which correspondence shall be redacted to exclude any material, non-public information regarding the Company or any of its Subsidiaries), (ii) after the same is prepared and filed with the Commission, one (1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by the Investor, and all exhibits and (iii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto; provided, however, the Company shall not be required to furnish any document (other than the Prospectus, which may be provided in .PDF format) to Legal Counsel to the extent such document is available on EDGAR).

 

(d)           Without limiting any obligation of the Company under the Purchase Agreement, the Company shall promptly furnish to the Investor, without charge, (i) after the same is prepared and filed with the Commission, at least one (1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by the Investor, all exhibits thereto, (ii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably request from time to time) and (iii) such other documents, including, without limitation, copies of any final Prospectus and any Prospectus Supplement thereto, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by the Investor; provided, however, the Company shall not be required to furnish any document (other than the Prospectus, which may be provided in .PDF format) to the Investor to the extent such document is available on EDGAR).

 

(e)            The Company shall take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and qualification applies, the resale by the Investor of the Registrable Securities covered by a Registration Statement under such other securities or “Blue Sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments (including, without limitation, post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and the Investor of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or “Blue Sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.

 

 8 

 

 

(f)            The Company shall notify Legal Counsel and the Investor in writing of the happening of any event, as promptly as reasonably practicable after becoming aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material, non-public information regarding the Company or any of its Subsidiaries), and, subject to Section 3(c), promptly prepare a supplement or amendment to such Registration Statement and such Prospectus contained therein to correct such untrue statement or omission and deliver one (1) electronic copy of such supplement or amendment to Legal Counsel and the Investor (or such other number of copies as Legal Counsel or the Investor may reasonably request). The Company shall also promptly notify Legal Counsel and the Investor in writing (i) when a Prospectus or any Prospectus Supplement or post-effective amendment has been filed, when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to Legal Counsel and the Investor by facsimile or e-mail on the same day of such effectiveness and by overnight mail), and when the Company receives written notice from the Commission that a Registration Statement or any post-effective amendment will be reviewed by the Commission, (ii) of any request by the Commission for amendments or supplements to a Registration Statement or related Prospectus or related information, (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate and (iv) of the receipt of any request by the Commission or any other federal or state governmental authority for any additional information relating to the Registration Statement or any amendment or supplement thereto or any related Prospectus. The Company shall respond as promptly as reasonably practicable to any comments received from the Commission with respect to a Registration Statement or any amendment thereto. Nothing in this Section 3(f) shall limit any obligation of the Company under the Purchase Agreement.

 

(g)            The Company shall (i) use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible time and (ii) notify Legal Counsel and the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.

 

(h)            The Company shall hold in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in such Registration Statement pursuant to the Securities Act, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company agrees that it shall, upon learning that disclosure of such information concerning the Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor, at the Investor’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

 9 

 

 

(i)            The Company shall cooperate with the Investor and, to the extent applicable, facilitate the timely preparation and delivery of Registrable Securities, as DWAC Shares, to be offered pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations as the Investor may reasonably request from time to time and registered in such names as the Investor may request. Investor hereby agrees that it shall cooperate with the Company, its counsel and Transfer Agent in connection with any issuances of DWAC Shares, and hereby represents, warrants and covenants to the Company that that it will resell such DWAC Shares only pursuant to the Registration Statement in which such DWAC Shares are included, in a manner described under the caption “Plan of Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations, including, without limitation, any applicable prospectus delivery requirements of the Securities Act. DWAC Shares shall be free from all restrictive legends may be transmitted by the transfer agent to the Investor by crediting an account at DTC as directed in writing by the Investor.

 

(j)            Upon the written request of the Investor, the Company shall as soon as reasonably practicable after receipt of notice from the Investor and subject to Section 3(n) hereof, (i) incorporate in a Prospectus Supplement or post-effective amendment such information as the Investor reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings of such Prospectus Supplement or post-effective amendment after being notified of the matters to be incorporated in such Prospectus Supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement or Prospectus contained therein if reasonably requested by the Investor.

 

(k)            The Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities.

 

(l)            The Company shall otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission in connection with any registration hereunder.

 

(m)            Within one (1) Business Day after each Registration Statement which covers Registrable Securities is declared effective by the Commission, the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to the Investor) confirmation that such Registration Statement has been declared effective by the Commission in a form to be provided by counsel to the Company and reasonably acceptable to the Investor.

 

 10 

 

 

(n)            Notwithstanding anything to the contrary contained herein (but subject to the last sentence of this Section 3(n)), at any time after the Effective Date of a particular Registration Statement, the Company may, upon written notice to Investor, suspend Investor’s use of any prospectus that is a part of any Registration Statement (in which event the Investor shall discontinue sales of the Registrable Securities pursuant to such Registration Statement contemplated by this Agreement, but shall settle any previously made sales of Registrable Securities) if the Company (x) is pursuing an acquisition, merger, tender offer, reorganization, disposition or other similar material transaction and the Company determines in good faith that (A) the Company’s ability to pursue or consummate such a material transaction would be materially adversely affected by any required disclosure of such transaction in such Registration Statement or other registration statement or (B) such material transaction renders the Company unable to comply with Commission requirements, in each case under circumstances that would make it impractical or inadvisable to cause any Registration Statement (or such filings) to be used by Investor or to promptly amend or supplement any Registration Statement contemplated by this Agreement on a post effective basis, as applicable, or (y) has experienced some other material non-public event the disclosure of which at such time, in the good faith judgment of the Company, would materially adversely affect the Company (each, an “Allowable Grace Period”); provided, however, that in no event shall the Investor be suspended from selling Registrable Securities pursuant to any Registration Statement for a period that exceeds 10 consecutive Trading Days or an aggregate of 30 days in any 365-day period; and provided, further, the Company shall not effect any such suspension during (A) the first 10 consecutive Trading Days after the Effective Date of the particular Registration Statement or (B) the five-Trading Day period following each settlement date for a Fixed Purchase, VWAP Purchase, or Additional VWAP Purchase, as applicable. Upon disclosure of such information or the termination of the condition described above, the Company shall provide prompt notice, but in any event within one Business Day of such disclosure or termination, to the Investor and shall promptly terminate any suspension of sales it has put into effect and shall take such other reasonable actions to permit registered sales of Registrable Securities as contemplated in this Agreement (including as set forth in the first sentence of Section 3(f) with respect to the information giving rise thereto unless such material, non-public information is no longer applicable). Notwithstanding anything to the contrary contained in this Section 3(n), the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the Investor in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which (i) the Company has made a sale to Investor and (ii) the Investor has entered into a contract for sale, and delivered a copy of the Prospectus included as part of the particular Registration Statement to the extent applicable, in each case prior to the Investor’s receipt of the notice of an Allowable Grace Period and for which the Investor has not yet settled.

 

4.Obligations of the Investor.

 

(a)            At least two (2) Business Days prior to the first anticipated filing date of each Registration Statement (or such shorter period to which the parties agree), the Company shall notify the Investor in writing of the information the Company requires from the Investor with respect to such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of the Investor that the Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request.

 

 11 

 

 

(b)            The Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of each Registration Statement hereunder, unless the Investor has notified the Company in writing of the Investor’s election to exclude all of the Investor’s Registrable Securities from such Registration Statement.

 

(c)            The Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(l) or the first sentence of 3(f), the Investor shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the Investor’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 3(l) or the first sentence of Section 3(f) or receipt of notice that no supplement or amendment is required. Notwithstanding anything to the contrary in this Section 4(c), the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the Investor in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which the Investor has entered into a contract for sale prior to the Investor’s receipt of a notice from the Company of the happening of any event of the kind described in Section 3(l) or the first sentence of Section 3(f) and for which the Investor has not yet settled.

 

(d)            The Investor covenants and agrees that it shall comply with the prospectus delivery and other requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to a Registration Statement.

 

5.Expenses of Registration.

 

All reasonable expenses of the Company, other than sales or brokerage commissions and fees and disbursements of counsel for, and other expenses of, the Investor, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.

 

 12 

 

 

6.Indemnification.

 

(a)            In the event any Registrable Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls the Investor within the meaning of the Securities Act or the Exchange Act and each of the directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons (each, an “Investor Party” and collectively, the “Investor Parties”), against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees, costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Claims”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the Commission, whether pending or threatened, whether or not an Investor Party is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under the securities or other “Blue Sky” laws of any jurisdiction in which Registrable Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus (as amended or supplemented) or in any Prospectus Supplement or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”). Subject to Section 6(c), the Company shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Investor Party arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by such Investor Party for such Investor Party expressly for use in connection with the preparation of such Registration Statement, Prospectus or Prospectus Supplement or any such amendment thereof or supplement thereto (it being hereby acknowledged and agreed that the written information set forth on Exhibit C attached hereto is the only written information furnished to the Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); (ii) shall not be available to the Investor to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the Prospectus (as amended or supplemented) made available by the Company (to the extent applicable), including, without limitation, a corrected Prospectus, if such Prospectus (as amended or supplemented) or corrected Prospectus was timely made available by the Company pursuant to Section 3(d) and then only if, and to the extent that, following the receipt of the corrected Prospectus no grounds for such Claim would have existed; and (iii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Investor Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant to Section 9.

 

 13 

 

 

(b)            In connection with any Registration Statement in which the Investor is participating, the Investor agrees to severally and not jointly indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an “Company Party”), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with written information relating to the Investor furnished to the Company by the Investor expressly for use in connection with such Registration Statement, the Prospectus included therein or any Prospectus Supplement thereto (it being hereby acknowledged and agreed that the written information set forth on Exhibit C attached hereto is the only written information furnished to the Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); and, subject to Section 6(c) and the below provisos in this Section 6(b), the Investor shall reimburse a Company Party any legal or other expenses reasonably incurred by such Company Party in connection with investigating or defending any such Claim; provided, however, the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld or delayed; and provided, further that the Investor shall be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the applicable sale of Registrable Securities pursuant to such Registration Statement, Prospectus or Prospectus Supplement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Company Party and shall survive the transfer of any of the Registrable Securities by the Investor pursuant to Section 9.

 

(c)            Promptly after receipt by an Investor Party or Company Party (as the case may be) under this Section 6 of notice of the commencement of any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Investor Party or Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Investor Party or the Company Party (as the case may be); provided, however, an Investor Party or Company Party (as the case may be) shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have failed promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company Party (as the case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any impleaded parties) include both such Investor Party or Company Party (as the case may be) and the indemnifying party, and such Investor Party or such Company Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Investor Party or such Company Party and the indemnifying party (in which case, if such Investor Party or such Company Party (as the case may be) notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof on behalf of the indemnified party and such counsel shall be at the expense of the indemnifying party, provided further that in the case of clause (iii) above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for all Investor Parties or Company Parties (as the case may be). The Company Party or Investor Party (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Company Party or Investor Party (as the case may be) which relates to such action or Claim. The indemnifying party shall keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Company Party or Investor Party (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Party or Investor Party (as the case may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include any admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately preceding sentence shall apply to Sections 6(a) and 6(b) hereof. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Company Party or Investor Party (as the case may be) with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Investor Party or Company Party (as the case may be) under this Section 6, except to the extent that the indemnifying party is materially and adversely prejudiced in its ability to defend such action.

 

 14 

 

 

(d)            No Person involved in the sale of Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in connection with such sale shall be entitled to indemnification from any Person involved in such sale of Registrable Securities who is not guilty of fraudulent misrepresentation.

 

(e)            The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred; provided that any Person receiving any payment pursuant to this Section 6 shall promptly reimburse the Person making such payment for the amount of such payment to the extent a court of competent jurisdiction determines that such Person receiving such payment was not entitled to such payment.

 

(f)            The indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company Party or Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

 

 15 

 

 

7.Contribution.

 

To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however: (i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification under the fault standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in connection with such sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the amount of net proceeds received by such seller from the applicable sale of such Registrable Securities pursuant to such Registration Statement. Notwithstanding the provisions of this Section 7, the Investor shall not be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by the Investor from the applicable sale of the Registrable Securities subject to the Claim exceeds the amount of any damages that the Investor has otherwise been required to pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

8.Reports Under the Exchange Act.

 

With a view to making available to the Investor the benefits of Rule 144, the Company agrees to:

 

(a)            so long as the Investor owns Registrable Securities, use its reasonable best efforts to make and keep public information available, as those terms are understood and defined in Rule 144;

 

(b)            so long as the Investor owns Registrable Securities, use its reasonable best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements (it being understood that nothing herein shall limit any of the Company’s obligations under the Purchase Agreement) and the filing of such reports and other documents is required for the applicable provisions of Rule 144;

 

(c)            furnish to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company, if true, that it has complied with the reporting, submission and posting requirements of Rule 144 and the Exchange Act, if applicable (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company with the Commission if such reports are not publicly available via EDGAR, and (iii) such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and

 

(d)            take such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company’s Transfer Agent as may be reasonably requested from time to time by the Investor and otherwise fully cooperate with Investor and Investor’s broker to effect such sale of securities pursuant to Rule 144.

 

 16 

 

 

9.Assignment of Registration Rights.

 

The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall not be deemed an assignment. The Investor may not assign its rights under this Agreement without the prior written consent of the Company, other than to an affiliate of the Investor controlled by Fredric Zaino, in which case the assignee must agree in writing to be bound by the terms and conditions of this Agreement.

 

10.Amendment or Waiver.

 

No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Trading Day immediately preceding the filing of the Initial Prospectus Supplement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

 

11.Miscellaneous.

 

(a)            Solely for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from such record owner of such Registrable Securities.

 

(b)            Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement shall be given in accordance with Section 9.4 of the Purchase Agreement.

 

(c)            Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof. The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

 17 

 

 

(d)            All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(e)            The Transaction Documents set forth the entire agreement and understanding of the parties solely with respect to the subject matter thereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written, solely with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth in the Transaction Documents. Notwithstanding anything in this Agreement to the contrary and without implication that the contrary would otherwise be true, nothing contained in this Agreement shall limit, modify or affect in any manner whatsoever (i) the conditions precedent to a Fixed Purchase, a VWAP Purchase or an Additional VWAP Purchase contained in the Purchase Agreement or (ii) any of the Company’s obligations under the Purchase Agreement.

 

(f)            This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors. This Agreement is not for the benefit of, nor may any provision hereof be enforced by, any Person, other than the parties hereto, their respective successors and the Persons referred to in Sections 6 and 7 hereof.

 

(g)            The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

(h)            This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

 18 

 

 

(i)            Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(j)            The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against any party.

 

[Signature Pages Follow]

 

 19 

 

 

IN WITNESS WHEREOF, Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first written above.

 

  COMPANY:
   
  ANNOVIS BIO, INC.
   
   
  By:  
    Name:
    Title:

 

 20 

 

 

IN WITNESS WHEREOF, Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first written above.

 

  INVESTOR:
   
  KEYSTONE CAPITAL PARTNERS, LLC
   
   
  By:   
    Name:
    Title:

 

 21 

 

 

EXHIBIT A

 

FORM OF NOTICE OF EFFECTIVENESS
OF REGISTRATION STATEMENT

 

[●]

[●]

[●]

 

Re:          Annovis Bio, Inc.

 

Ladies and Gentlemen:

 

We are counsel to Annovis Bio, Inc., a Delaware corporation (the “Company”), and have represented the Company in connection with that certain Common Stock Purchase Agreement, dated [ ], 2024 (the “Purchase Agreement”), entered into by and among the Company and the Investor named therein (the “Holder”) pursuant to which the Company will issue to the Holder from time to time shares of the Company’s common stock, par value $0.0001 per share (the ”Common Stock”). Pursuant to the Purchase Agreement, the Company also has entered into a Registration Rights Agreement, dated [ ], 2024, with the Holder (the “Registration Rights Agreement”), pursuant to which the Company agreed, among other things, to register the offer and sale by the Holder of the Registrable Securities (as defined in the Registration Rights Agreement) under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the Company’s obligations under the Registration Rights Agreement, on [●], 2024, the Company filed a Registration Statement on Form S-3 (File No. 333-276814) (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) relating to the Registrable Securities which names the Holder as an underwriter and a selling stockholder thereunder.

 

In connection with the foregoing, based solely on our review of the Commission’s EDGAR website, we advise you that the Registration Statement became effective under the Securities Act on [●], 2024. In addition, based solely on our review of the information made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml, we confirm that the Commission has not issued any stop order suspending the effectiveness of the Registration Statement. To our knowledge, based solely on our participation in the conferences mentioned above regarding the Registration Statement and our review of the information made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml, no proceedings for that purpose are pending or have been instituted or threatened by the Commission.

 

This letter shall serve as our standing opinion to you that the shares of Common Stock are freely transferable by the Holder pursuant to the Registration Statement, provided the Registration Statement remains effective.

 

This opinion letter is limited to the federal securities laws of the United States of America. We express no opinion as to matters relating to state securities laws or Blue Sky laws.

 

We assume no obligation to update or supplement this opinion letter to reflect any facts or circumstances which may hereafter come to our attention with respect to the opinion and statements expressed above, including any changes in applicable law that may hereafter occur.

 

 

 

This opinion letter is being delivered solely for the benefit of the person to whom it is addressed; accordingly, it may not be quoted, filed with any governmental authority or other regulatory agency or otherwise circulated or utilized for any purposes without our prior written consent.

 

  Very truly yours,
   
  [______________________________________________________]
   
  By:                                                                                                            
cc:  

 

 

 

 

EXHIBIT B

 

SELLING STOCKHOLDER

 

This prospectus relates to the possible resale from time to time by Keystone Capital Partners of any or all of the shares of common stock that may be issued by us to Keystone Capital Partners under the Purchase Agreement. For additional information regarding the issuance of common stock covered by this prospectus, see the section titled “Keystone Capital Partners Committed Equity Financing” above. We are registering the shares of common stock pursuant to the provisions of the Registration Rights Agreement we entered into with Keystone Capital Partners on [_], 2024 in order to permit the selling stockholder to offer the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement, Keystone Capital has not had any material relationship with us within the past three years. As used in this prospectus, the term “selling stockholder” means Keystone Capital Partners, LLC.

 

The table below presents information regarding the selling stockholder and the shares of common stock that it may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the selling stockholder, and reflects holdings as of [●], 2024. The number of shares in the column “Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus” represents all of the shares of common stock that the selling stockholder may offer under this prospectus. The selling stockholder may sell some, all or none of its shares in this offering. We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares.

 

Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the selling stockholder has voting and investment power. The percentage of shares of common stock beneficially owned by the selling stockholder prior to the offering shown in the table below is based on an aggregate of [●] shares of our common stock outstanding on [●], 2024. Because the purchase price of the shares of common stock issuable under the Purchase Agreement is determined on each Fixed Purchase Date, with respect to a Fixed Purchase, on the applicable VWAP Purchase Date, with respect to a VWAP Purchase, and on the applicable Additional VWAP Purchase Date, with respect to an Additional VWAP Purchase, the number of shares that may actually be sold by the Company to Keystone Capital under the Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the selling stockholder pursuant to this prospectus.

 

 

 

 

    Number of Shares of
Common Stock Owned
Prior to Offering
    Maximum Number of
Shares of Common Stock
to be Offered Pursuant
to this
    Number of Shares of
Common Stock Owned
After Offering
 
Name of Selling Stockholder   Number(1)     Percent(2)     Prospectus     Number(3)     Percent(2)  
Keystone Capital Partners, LLC(4)     [________]       *        [●]        0        --   

 

 

*Represents beneficial ownership of less than [_]% of the outstanding shares of our common stock.
(1)This number represents the [________] shares of common stock we issued to Keystone Capital Partners on [_], 2024 as Commitment Shares in consideration for entering into the Purchase Agreement with us. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Keystone Capital may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Keystone Capital’s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Fixed Purchases, VWAP Purchase, or Additional VWAP Purchase, as applicable, of common stock are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock to Keystone Capital to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Keystone Capital, would cause Keystone Capital’s beneficial ownership of our common stock to exceed the 4.99% Beneficial Ownership Cap.
(2)Applicable percentage ownership is based on [●] shares of our common stock outstanding as of [●], 2024.
(3)Assumes the sale of all shares being offered pursuant to this prospectus.
(4)The business address of Keystone Capital Partners, LLC is 139 Fulton Street, Suite 412, New York, NY 10038. Keystone Capital Partners, LLC’s principal business is that of a private investor. Ranz Group, LLC, a Delaware limited liability company, is the managing member of Keystone Capital Partners, LLC and the beneficial owner of 97% of the membership interests in Keystone Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC and has sole voting control and investment discretion over securities beneficially owned directly by Keystone Capital, LLC and indirectly by Ranz Group, LLC. We have been advised that none of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned directly by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC.

 

 

 

 

PLAN OF DISTRIBUTION

 

The shares of common stock offered by this prospectus are being offered by the selling stockholder, Keystone Capital Partners, LLC.  The shares may be sold or distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the shares of our common stock offered by this prospectus could be effected in one or more of the following methods:

 

ordinary brokers’ transactions;
   
transactions involving cross or block trades;
   
through brokers, dealers, or underwriters who may act solely as agents;
   
“at the market” into an existing market for our common stock;
   
in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;
   
in privately negotiated transactions; or
   
any combination of the foregoing.

 

In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state’s registration or qualification requirement is available and complied with.

 

Keystone Capital Partners, LLC is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.

 

Keystone Capital has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that it has acquired and may in the future acquire from us pursuant to the Purchase Agreement.  Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price.  Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act.  Keystone Capital has informed us that each such broker-dealer will receive commissions from Keystone Capital that will not exceed customary brokerage commissions.

 

Brokers, dealers, underwriters or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the selling stockholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our common stock sold by the selling stockholder may be less than or in excess of customary commissions.  Neither we nor the selling stockholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our common stock sold by the selling stockholder.

 

 

 

 

We know of no existing arrangements between the selling stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common stock offered by this prospectus.

 

We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the selling stockholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the selling stockholder, any compensation paid by the selling stockholder to any such brokers, dealers, underwriters or agents, and any other required information.

 

We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our common stock covered by this prospectus by the selling stockholder. As consideration for its irrevocable commitment to purchase our common stock under the Purchase Agreement, we have issued to Keystone Capital ________ shares of our common stock as Commitment Shares in accordance with the Purchase Agreement. We have also paid to Keystone Capital $25,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by Keystone Capital, including the legal fees and disbursements of Keystone Capital’s legal counsel, in connection with its due diligence investigation of the Company and in connection with the preparation, negotiation and execution of the Purchase Agreement.

 

We also have agreed to indemnify Keystone Capital and certain other persons against certain liabilities in connection with the offering of shares of our common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.  Keystone Capital has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Keystone Capital specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

 

We estimate that the total expenses for the offering will be approximately $[●].

 

Keystone Capital has represented to us that at no time prior to the date of the Purchase Agreement has Keystone Capital or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock.  Keystone Capital has agreed that during the term of the Purchase Agreement, neither Keystone Capital, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.

 

 

 

 

We have advised the selling stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.

 

This offering will terminate on the date that all shares of our common stock offered by this prospectus have been sold by the selling stockholder.

 

Our common stock is currently listed on The New York Stock Exchange under the symbol “ANVS”.

 

 

 

 

EXHIBIT C

 

The business address of Keystone Capital Partners, LLC is 139 Fulton Street, Suite 412, New York, NY 10038. Keystone Capital Partners, LLC’s principal business is that of a private investor. Ranz Group, LLC, a Delaware limited liability company, is the managing member of Keystone Capital Partners, LLC and the beneficial owner of 97% of the membership interests in Keystone Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC and has voting control and investment discretion over securities beneficially owned directly by Keystone Capital, LLC and indirectly by Ranz Group, LLC. We have been advised that none of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned directly by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC.

 

 

 

EX-101.SCH 4 anvs-20240402.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 anvs-20240402_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 anvs-20240402_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 25, 2024
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 101 Lindenwood Drive
Entity Address, Address Line Two Suite 225
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 875-3192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports anvs-20240402.xsd anvs-20240402_lab.xml anvs-20240402_pre.xml tm2412796d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2412796d1_8k.htm": { "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20240402", "dts": { "schema": { "local": [ "anvs-20240402.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20240402_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20240402_pre.xml" ] }, "inline": { "local": [ "tm2412796d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412796d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412796d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-052471-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-052471-xbrl.zip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tm2412796d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2024-04-25 2024-04-25 iso4217:USD shares iso4217:USD shares false 0001477845 8-K 2024-04-25 ANNOVIS BIO, INC. DE 001-39202 26-2540421 101 Lindenwood Drive Suite 225 Malvern PA 19355 484 875-3192 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true false